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Foreword 
 
The following thesis is divided into chapters One and Two. Chapter One and first part of chapter Two 
will focus on research activities conducted at the University of Cagliari during the first eighteen months 
of my Ph.D. program. This research led to three published articles and another one in progress that will 
soon be submitted for peer review (data not discussed). From the end of May 2012 until November 2013 
I was involved in a graduate partnership program as supplemental visiting fellow at the Rocky Mountains 
Laboratories, a National Institutes of Health (NIH) facility located in Hamilton (Montana, USA); research 
conducted during this experience led to the article discussed in second part of chapter Two. 
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Chapter 1 
Development of a novel approach to predict and quantify the synergism of anti-
cancer drugs using experimental design and artificial neural networks 
 
Introduction and rationale 
The treatment of cancer is mostly based on a multidrug strategy. The administration of more than one 
drug at the same time aims to avoid the increase of drug resistant cells and reduce the dose of each drug 
of the combination, exploiting the synergistic effect. At the moment the evaluation of the synergistic 
effect is mainly performed using the Combination Index (CI) method and also Isobolograms (IB). The 
CI method is based on the assumption that the effect of the drugs is due only to the inhibition of enzyme 
kinetics (Chou et al. 1981). This assumption is not valid for any kind of drug in use; it is well known and 
studied that also other mechanisms can be involved. Cisplatin (CDDP) is one example of anticancer drug 
that has a different mechanism of action than direct effect on enzymes. Moreover, both CI and IB 
methods can only establish the effectiveness of the drug combination experimentally tested. We tried to 
overcome the limits of the classical approach using the Experimental Design (ED) and Artificial Neural 
Networks (ANNs); this approach, in fact, could not only allow to better quantify the degree of drug 
synergism of the tested combinations, but also to predict the effect of all possible drug doses, leading to 
the identification of the combination with the most powerful synergistic effect.   
An ANN is a powerful mathematical tool in the form of a computer software that recreates the structure 
and the functions of a biological brain. It is composed by logic units called “neurons” organized in 3 
layers: input, hidden and output. After an appropriate “learning” process the ANN is able to predict the 
response for values of inputs never used before. The learning process is performed with a limited number 
of experiments that produce input data for the network called “training set”.  
A previous study (published by Journal of Inorganic Biochemistry) allowed us to evaluate anti-cancer activity 
of new copper(II)-phenantroline complexes (Pivetta et al. 2011) versus human hematologic (CCRF-CEM 
and CCRF-SB) and solid tumor-derived cell lines (K-MES-1 and DU-145); afterwards, ANN method 
was applied to binary mixtures of these new copper(II) complexes with CDDP tested against CCRF-
CEM. 
The latter study was performed thanks to the joined efforts with a group of chemists of the University 
of Cagliari and from the Masaryk University (Brno, Czech Republic). The results obtained confirmed our 
hypothesis and were recently published by Talanta (see following articles). 
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Cu(II) complexes with 1,10-orthophenanthroline (phen) show cytotoxic and antitumoral effects. To enhance
and exploit these features, we studied complexes containing one or two phen units together with N,N′-
substituted-imidazolidine-2-thione (L). We synthesized and structurally characterized the precursor mole-
cule Cu(phen)(OH2)2(OClO3)2, and determined the complex formation constants of [Cu(phen)(L)]2+. We
studied the cytotoxic activity of [Cu(phen)2(L)](ClO4)2 versus human hematologic (CCRF-CEM and CCRF-
SB) and solid tumor-derived cell lines (K-MES-1, DU-145). The cytotoxic activities, in the 1–3 μM range,
show that our Cu(II)–complexes possess comparable inhibitory activities against both leukemia and carcino-
ma cells, unlike the majority of antineoplastic agents, usually more potent against hematologic cancer cells
than against solid tumor cells. Because the free Cu(II) ion is reduced by glutathione (GSH), we studied the re-
activity of our complexes with GSH, providing evidence that no redox reaction occurred under the chosen ex-
perimental conditions. Complex formation equilibria were present, studied by spectrophotometric titrations.
The redox properties of the prepared compounds were also investigated by cyclic voltammetry, conﬁrming
that the mixed Cu(II) complexes were resistant to reduction.
© 2012 Elsevier Inc. All rights reserved.
1. Introduction
Copper(II) is involved in several biological processes, in particular in
redox reactions [1,2], catalyzing the generation of reactive oxygen spe-
cies. Complexes of copper(II) with 1,10-ortho-phenanthroline (phen)
are capable of cleaving DNA [3,4] and improve nuclease activity [3,5–7]
showing cytotoxic [8], genotoxic [9] and antitumoral effects[10], both
in vitro and in vivo.
The couple Cu(II)/Cu(I) is also involved in the reactions with gluta-
thione. In living systems, glutathione exists in two forms, reduced
(GSH) and oxidized glutathione disulﬁde (GSSG). GSH prevents dam-
age to important cellular components by forming complexes with sev-
eral metal ions [11–14] and by reducing the Cu(II) ion [15]. As a
consequence, the cytotoxicity of Cu(II) complexes may be strongly
modiﬁed by reactionswith GSH, inside or outside the cells. The reduced
Cu(I)-complexes could lead to unexpected reactions and interfere with
different molecular processes, all generating potential side effects.
Recently, we prepared a series of new copper(II) complexes, con-
taining two phenanthrolinic units and N,N′-substituted-imidazolidine-
2-thione (L1–L4, Fig. 1) as auxiliary ligands [16]; these compounds are
characterized by a high chemical stability coupled with high cytotoxic
activity against mouse neuroblastoma N2a cell lines. In the light of
these results andwith the aimof obtaining amoleculewith improved cy-
totoxic or antiproliferative activity, it seemed very interesting to prepare
new mixed compounds by varying the number of chelating units and
auxiliary ligands. In addition, we deemed that it is fundamental to
study the reactivity of these complexes in the presence of glutathione
in order to verify their stability, and eventually to identify the possible
by-reactions. We applied a multidisciplinary approach, covering
many ﬁelds: bio-, analytical, inorganic and physic-chemistry. We
synthesized and structurally characterized the Cu(II) complex
Cu(phen)2(OH2)2(OClO3)2, 1; determined the complex formation
constants of [Cu(phen)]2+ with L1–L4 and studied the reactivity
of the chelate complexes [Cu(phen)x]2+ (where x=1, 2, 3) and
[Cu(phen)2L1]2+ with GSH at pH 7.4 in 0.1 M phosphate buffer.
Moreover we extended the study in vitro of the cytotoxic activity
of C1–C4 [Cu(phen)2L]2+ complexes (L= L1–L4) to human hematolog-
ic tumor-derived cell lines, i.e. human acute T-lymphoblastic leukemia
(CCRF-CEM) and acute B-lymphoblastic leukemia (CCRF-SB), and to
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solid tumor-derived cell lines, i.e. lung squamous carcinoma (K-MES-1)
and prostate carcinoma (DU-145). The synthesized and studied com-
plexes are shown in Fig. 1.
2. Experimental section
2.1. Materials and methods
2.1.1. Reagents
Cu2(CO3)(OH)2, 1,10-phenanthroline monohydrate, glutathi-
one, glutathione disulﬁde, perchloric acid, ethanol, ethylic ether,
orthophosphoric acid, potassium hydroxide, dimethyl sulfoxide
(DMSO), ethylenediaminetetraacetic acid (EDTA), and ligand L1 were
purchased from Sigma-Aldrich and used without any further puriﬁca-
tion. The stock solutions of Cu(II) compoundswere prepared by dissolv-
ing the proper amount of sample in 0.1 M phosphate buffer of pH 7.4.
The analytical concentration of Cu(II) was measured by spectrophoto-
metric titrationwith EDTA. GSH puritywas evaluated by elemental anal-
ysis.CAUTION: Perchlorate complexes are potentially explosive, handle these
compounds even in small amounts with care.
2.1.2. UV–visible (UV–vis) spectrophotometric measurements
The UV–vis measurements were carried out with a Varian Cary 50
spectrometer equipped with an optical ﬁber dip probe with a 1 cm op-
tical path length.
2.1.3. Conductometric measurements
The conductometric measurements were carried out with a AMEL
2131 - conductivity meter in aqueous solution at 20 °C.
2.1.4. Spectrophotometric titrations and constants deﬁnition
The complex formation equilibria were studied by a spectrophoto-
metric titration, at 25 °C at pH 7.4 in a 0.1 M phosphate buffer, following
the spectral variations due to the addition of the titrant. This methodwas
applicable because the species formed at different titrant/titrand molar
ratios were characterized by absorption peaks dissimilar for position
and intensity [17,18]. Being the absorbance correlated to the species con-
centration, a complexation model was proposed and the experimental
data were ﬁtted minimizing the difference between the calculated and
experimental absorbance. The equilibrium constants were expressed tak-
ing into account the following considerations and conventions.
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Fig. 1. Acronyms and pictograms of the studied compounds.
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The general equation for the equilibria of complex formation is
shown by eq. 1 in Scheme 1, and the thermodynamic deﬁnition of the
global formation constant (or overall association constant) is deﬁned as
βp,q (eq. 2), where the symbol {i} indicates the activity of the i-th species.
It is straightforward that for the inverse equilibrium(eq. 3), the instability
constant (or dissociation constant) of the complexMpLq is given by eq. 4.
When a constant ionic medium is used, formal concentration terms are
used in place of activities according to the deﬁnition of Schwarzenbach's
side reaction coefﬁcients (ξi) [19] as shownby eq. 5. It is clear that for sys-
tems where several equilibria take place, a set of equilibrium equations
has to be considered. The overall formation constants of the type βi,j
can bewritten as the product of the stepwise constants (Kj). For example,
the overall formation constant for the speciesMLnmay be expressed as in
eqs. 6 and 7.
The constants presented in the work were obtained by using the
Hyperquad program [20], which uses the convention that all equilib-
rium constants are expressed as overall association constants.
2.1.5. I.R. spectrophotometric measurements
Infrared spectra were recorded in a Bruker Vector 22 spectropho-
tometer, preparing the samples as KBr pellets.
2.1.6. XPRD spectrophotometric measurements
X-ray powder diffraction patterns were recorded using a J–J diffrac-
tometer (Seifert X3000) with Bragg–Brentano geometry and CuKα radi-
ation. Before themeasurements, the samples were groundwith an agate
mortar and the obtained ﬁne powders were dispersed in ethanol, soni-
cated, deposited drop by drop on a silicon zero background sample hold-
er, and dried in air. The samples in the formof powderswere observed in
electronmicrographs obtained using a transmission electronmicroscope
(JEOL 200CX) operating at 200 kV. Finely ground samples were dis-
persed in n-octane and subjected to an ultrasonic bath. The suspensions
were then dropped on carbon-coated copper grids for observation.
2.1.7. Cyclic voltammetry experiments
Cyclic voltammetry experiments were carried out on an Autolab
PGSTAT12 potentiostat/galvanostat, equipped with a working-counter
double-Pt electrode, an Ag/AgCl reference electrode, under an Ar atmo-
sphere at 25 °C at pH 7.4 in 0.1 M phosphate buffer. The electrodes
were rinsed with a 1:1 solution of HNO3/H2O2 andwashedwith distilled
water after each experiment. The solutions (5 mL) were degassed with
Ar for 10 min before the measurements.
2.2. Synthesis
1: Concentrated perchloric acid (0.5 mL, 4.6 mmol) was slowly
added to an ethanol suspension of Cu2(CO3)(OH)2 (0.2 g, 1.8 mmol
of Cu(II), 20 mL), stirring and warming until complete solubilization.
The resulting deep blue solution was cooled and an ethanol solution
of phen (0.09 g, 0.45 mmol, 20 mL) was added. The solution was ﬁl-
tered in order to remove any trace of the insoluble by-product 2.
The solution was concentrated under vacuum at approx. 5 mL of vol-
ume, and allowed to crystallize for 2 days. The deep blue crystals were
ﬁltered off and dried at room temperature. Percentage yield 43%; anal.
calcd. for Cu(phen)(OH2)2(ClO4)2: C 30.11, H 2.53, N 5.85, found: C
29.78, H 2.49, N 5.78. IR (KBr cm−1) selected bands ν(O–H) 3407, ν
(phen group) 3079, 3052, 1585, 1520, 1424, 1347, 853, 722, 627; ν (per-
chlorate group) 1145, 1110, 1086. Blue crystals suitable for X-ray analy-
siswere obtained and the crystal structurewas solved. The powder X-ray
diffraction (PXRD) spectrum was collected and indexed using the
corresponding CIF ﬁle with the Mercury program [21] (Supplementary
information (S.I.), Fig. S1a).
2: This compound was prepared as previously reported [16]. The
PXRD spectrum was collected and indexed using the corresponding
CIF ﬁle with the Mercury program [21] (S.I., Fig. S1b).
3: This compound was prepared by the reaction between 2 (0.3 g,
0.47 mmol) and phen (0.094 g, 0.47 mmol) in 40 mL of ethanol. The
blue precipitate was ﬁltered, washed with ethanol and dried at room
temperature. Percentage yield 95%, anal. calcd. For 3: C 53.84, H 3.01, N
10.46, found C 53.95, H 3.55, N 10.55.
C1–C4: The mixed compounds C1–C4 [Cu(phen)2L](ClO4)2 (L =
L1–L4) were prepared as previously reported [16]. Any attempt to ob-
tain [Cu(phen)L](ClO4)2 in a solid state from water or water/CH3CN
solution led to the corresponding [Cu(phen)2L](ClO4)2 compound.
The PXRD spectrum of C1 was collected and indexed using the
corresponding CIF ﬁle with the Mercury program [21] (S.I., Fig. S1c).
3-GSH and 2-GSH systems: 0.12 g of GSH (0.37 mmol, 10 mL) was
added to a water suspension containing 0.30 g of 3 (0.37 mmol,
25 mL). A blue–violet precipitate was isolated, washed with water,
and dried at room temperature (yield 68%); from the ﬁltered solution,
crystals of phen were recovered. 0.14 g of GSH (0.47 mmol, 10 mL)
was added to a water suspension containing 0.30 g of 2 (0.47 mmol,
25 mL). A blue–violet precipitate was isolated, washed with water,
and dried at room temperature (yield 75%). Both products were ana-
lyzed by I.R. andUV–vis spectroscopy, showing that theywere identical.
By adding HCl to a water suspension of the blue–violet compound, we
observed the precipitation of GSH and 3 or 2, then by adding NaOH,
the blue–violet compound was reversibly regenerated. A portion of
≈0.08 g was treated with H2O2/HNO3 to oxidize the possibly present
Cu(I) to Cu(II) and titrated with EDTA, another portion was titrated as
such; both titrations gave the same Cu(II) content (9.94%), showing
that only Cu(II) ion was present in the sample. The blue–violet com-
pound is stable even if exposed to air for several months.
2.3. Cell lines
The following human cell lines were purchased from the American
Type Culture Collection (ATCC, USA): CCRF-CEM (acute T-lymphoblastic
leukemia), CCRF-SB (acute B-lymphoblastic leukemia), K-MES-1 (lung
squamous carcinoma), and DU-145 (prostate carcinoma). All cell lines
were grown at 37 °C in a 5% CO2 atmosphere in their speciﬁc
media and according to ATCC instructions in the presence of 10%
fetal calf serum (FCS), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin. All cell lines were maintained in exponential growth by pe-
riodically splitting high density suspension cultures (i.e. 106/mL)
of CCRF-CEM and CCRF-SB, or when K-MES-1 and DU-145 cell
monolayers reached sub-conﬂuence. Cell cultures were periodically
tested for the absence of mycoplasma contamination.Scheme 1. Equations used in the deﬁnition of the complex formation constants.
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2.4. Cytotoxic assay
The cytotoxic effect of test compounds was evaluated in exponen-
tially growing cell cultures. Stock solutions of test compounds were
made at 1 mM in DMSO and stored at 4 °C in the dark. For the evalu-
ation of cytotoxicity, each compound was serially diluted in speciﬁc
growth medium for the different cell lines so that the concentration
of DMSO was never higher than 0.1%. Leukemia and solid tumor
cells were seeded at an initial density of 2×105 cells/mL in a ﬂat-
bottom 96-well plate in their speciﬁc media supplemented with 10%
FCS and antibiotics as described above, and incubated overnight be-
fore the addition of 2× serial dilutions of test compounds. Cell growth
in the absence and in the presence of test compounds was determined
after 96 h of incubation, corresponding to three duplication rounds of
untreated cells, by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra-
zolium bromide (MTT) method [22]. Numbers of viable cells were also
determined by the trypan blue dye exclusion method. Cell growth at
each drug concentration was expressed as the percentage of untreated
controls. The 50% cytotoxic concentration (CC50) was determined from
the dose–response curves by linear regression. Values are reported as
the mean±standard deviation of quadruplicate determinations for each
drug concentration. Each compoundwas tested in at least three indepen-
dent assays. Statistical analysis was performed with Student's t-test, and
signiﬁcance was set at p≤0.05. The antitumor agent 6-mercaptopurine
(6MP) was used as a reference compound.
2.5. Crystallographic data of 1
C12H12Cl2CuN2O10,M=478.68, triclinic, a=7.840(2), b=10.591(2),
c=10.905(2) Å, α=76.06(3), β=75.80(3), γ=78.35(3)°, U=842.0(3)
Å3, T=294(2) K, space group P-1 (no. 2), Z=2, μ=(Mo-Kα)
1.674 mm−1. 9806 reﬂections (5126 unique; Rint=0.021)were collected
at room temperature in the range 3.94°b2θb62.76°, employing a
0.13×0.04×0.03 mm crystal mounted on a Bruker APEX II CCD diffrac-
tometer and using graphite-monochromatized Mo-Kα radiation (λ=
0.71073 Å). Final R1 [wR2] values were 0.0376 [0.1216] on I>2σ(I) [all
data]. Datasets were corrected for Lorentz polarization effects and for ab-
sorption with the Siemens Area Detector Absorption (SADABS) correc-
tion program [23]. The structure was solved by direct methods (SIR-
97) [24] and was completed by iterative cycles of full-matrix least
squares reﬁnement on Fo2 and ΔF synthesis using the SHELXL-97 [25]
program (WinGX suite) [26]. Hydrogen atoms located on the ΔF maps
were allowed to ride on the carbon atoms for the phenanthroline ligand,
whereas those of the water molecules were reﬁned. Crystallographic
data for compound 1 (excluding structure factors) have been deposited
with the Cambridge Crystallographic Data Centre as supplementary pub-
lication no. CCDC-848420. These data can be obtained free of charge at
www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union
Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033; e-mail: deposit@
ccdc.cam.ac.uk).
3. Results and discussion
3.1. Synthesis and crystal structure of 1
The synthesis of 1was carried out with a stoichiometric deﬁciency of
phen in order to avoid the formation of the most stable complex 2. The
X-ray crystal structure of 1 has also been recently reported by Kaabi et
al. [27]. It contains [Cu(phen)(H2O)2]2+ cations with the copper atoms
in octahedral coordination and perchlorate anions. The latter interact
with the copper ion at the two apical positions of the coordination
sphere, with Cu–O distances of 2.419(3) and 2.577(3) Å, respectively,
and with one of the two water molecules through two intramolecular
hydrogen bonds [O4…H3w-Ow2 140(5)°, O4…Ow2 2.807(7) Å; O6…
H4w-Ow2 166(5)°, O6…Ow2 2.866(4) Å]. The phenanthroline ligand
and the two water molecules occupy the equatorial positions of the
octahedron. Intermolecular hydrogen bonds between the coordinated
water molecules and the perchlorate anions are present: O6…H1w-
Ow1 (1-x,1-y,1-z) 160(4)°, O6…Ow1 2.794(3) Å; O2…H2w-Ow1
(1+x,y,z) 173(4)°, O2…Ow1 2.743(4) Å; O4…H3w-Ow2 (−x,1-y,1-z)
108(4)°, O4…Ow2 2.790(4) Å. In addition the phenanthroline units of
adjacent complex molecules, are associated by π–π stacking interactions
at a distance of about 3.54 Å, a value signiﬁcantly lower than the limit
value for π–π interaction of 3.8 Å [28].
The structure of the present complex is similar to that of Cu(2,2′-
bipyridine)(OH2)2(OClO3)2 [29], also in this compound copper ion is
coordinated by the perchlorate groups. Cu–Nand Cu–Odistances are lon-
ger in 1 (average Cu–N 1.988 Å vs. 1.977 Å; average Cu–O 2.498 Å vs
2.417 Å), while Cu–Ow distances are quite similar (1.964 Å vs. 1.967).
The elongating effect of Cu–N and Cu–O distances might be due to the
sterical hindrance of the phen, bigger than that of the 2,2′-bipyridine.
A comparison of the structure of 1 with that of [Cu(phen)2(H2-
O)](ClO4)2 [30], where the coordination of the copper ion is trigonal bi-
pyramidal and no perchlorate anions interact with themetal ion, shows
that the Cu–Ow distances are deﬁnitely shorter in our case (average
1.964(2) Å vs. 2.245(4) Å)whereas the Cu–N distances are almost com-
parable (1.993(2) Å vs. 2.007(3) Å). This shortening effect is in agree-
ment with the different coordination number of the copper ion which
in the present case displays a 4+2 coordination geometry instead of
5. Some views of the structure are reported in Fig. 2.
3.2. Conductometric measurements
In order to establish the kind of electrolyte of the studied copper com-
pounds, themolar conductivity of their aqueous solution was measured.
The values obtained, in the range 228–260 S cm2 mol−1 (237 for 1, 245
for 2, 228 for 3, 237 for C1, 260 for C2 and C3, 235 for C4), show that all
the complexes have electrolyte nature. Moreover, being the molar con-
ductivity of the complexes comparable with that of [Cu(phen)3](ClO4)2
which is deﬁnitely a 1:2 electrolyte, all the studied copper compounds
have the same 1:2 electrolyte nature. This also means that in solution
both the perchlorate anions are outside the copper coordination sphere.
3.3. Cytotoxic activity
We exploited the ability of Cu(II) complexes to inhibit the growth
of tumor cells in vitro as a measure of their potential anticancer phar-
macological effect. For each compound, we determined its CC50, i.e.
the drug concentration that inhibits cell growth by 50%. We employed
four human cancer-derived cell lines: two from hematological can-
cers (CCRF-CEM acute T-lymphoblastic leukemia and CCRF-SB acute
B-lymphoblastic leukemia) and two from carcinomas (K-MES-1 lung
squamous carcinoma and DU-145 prostate carcinoma). The results
are summarized in Table 1. Complexes 1 and C1–C4 showed antip-
roliferative activity in the micromolar or submicromolar range, while li-
gands L1–L4 were totally devoid of any inhibitory effect even at the
maximum concentration tested (100 μM). Complex 2 appeared more
cytotoxic than 1 due to the presence of two phen units. The insertion
of the thionic ligands L on the core of 2 produced different effects on
the corresponding cytotoxic activity towards the four tumor cell lines,
most probably because of the different hydrophilicity/lipophilicity of
the resulting molecules.
Lipophilicity/hydrophilicity of amolecule is correlated to the octanol/
water partition coefﬁcient P ormore properly to the logP [31]. This prop-
erty indicates the extent of diffusion of a molecule in the target organs.
Log p value gives useful information for neutralmolecules such as the or-
ganic ligands, but it is not adequate for the charged molecule and for
strong electrolytes. Our complexes are strong electrolytes and are almost
insoluble in octanol (no spectral variation occurred for thewater solution
of copper complexes before and after the contactwith n-octanol). To dis-
tinguish the lipophilicity/hydrophilicity of our complexes we think it is
useful to compare their calculated dipole moments, in fact the higher
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the dipolemoment, the higher the hydrophilicity. The dipolemoment of
our mixed complexes is in the order C1>C2>C4>C3 (3.13, 2.06, 1.05
and 0.95 debye respectively). C3 and C4 derivatives with the thionic li-
gands featuring two methyl and one ethyl group respectively, present
the lower dipole moment values and are more active with solid cancer
than with leukemia, while C1 and C2 derivatives, the ﬁrst un-
substituted and the second with only one methyl group, present the
higher dipole moment values and are more active with hematological
cancer cells. The correspondence of the dipole moment and the kind
of activity, i.e. versus solid or liquid cancer cells, suggest that the choice
of the substituents, which vary the lipophilicity/hydrophilicity, may
play an important role in the selection of the proper drug in the treat-
ment of the cancer cells.
Unlike the majority of antineoplastic agents, which are usually
markedly more potent against hematologic cancer cells than against
solid tumor cells, all the studied Cu(II) complexes showed comparable
inhibitory activities against both leukemic and carcinoma cells. The cyto-
toxic activity of our complexes result very interesting if compared with
the activity of other metal complexes, in fact the most of the metal com-
plexes and many drugs have a CC50 values in the range 10–20 μM.
Cisplatinum for example has a 15 μM CC50 value for A-498 cell line and
Fig. 2. ORTEP (A) and views of the crystal packing (B, C) of 1.
Table 1
Cytotoxicity activity of the studied compounds reported as CC50; the standard deviations
of three independent experiments are reported in parentheses.
Comp. CC50[μM]a
CCRF-CEMb CCRF-SBc SKMES-1d DU145e
1 3.2 (1) 1.4 (1) 1.9 (1) 2.6 (3)
2 1.25 (2) 0.50 (5) 0.93 (6) 1.6 (2)
C1 0.80 (8) 0.70 (7) 0.85 (4) 1.6 (2)
C2 0.80 (8) 0.60 (5) 0.97 (7) 3.6 (4)
C3 0.90 (9) 0.80 (7) 0.7 (1) 1.50 (5)
C4 1.1 (1) 1.3 (1) 0.9 (1) 1.5 (2)
L1–L4 >100 >100 >100 >100
6MPf 2.0 (2) 0.70 (8) >100 2.0 (1)
a CC50, compound concentration required to reduce cell proliferation by 50%, as de-
termined by the MTT method, under conditions allowing untreated controls to under-
go at least three consecutive rounds of multiplication.
b CCRF-CEM CD4+, human acute T-lymphoblastic leukemia.
c CCRF-SB, human acute B-lymphoblastic leukemia.
d SKMES-1, human lung squamous carcinoma.
e DU145, human prostate carcinoma.
f 6MP, 6-mercaptopurine, usually used in combination with other drugs for mainte-
nance therapy of acute lymphoblastic leukemia.
Table 2
Complex formation constants for the system Cu(II)–phen-L.
System logβ1 logβ2 logK1 logK2
Cu(II)+phen 8.14 (1)a 12.23(1)a 8.14 4.09
1+L1 11.56 (1)b 15.16 (1)b 4.72 3.60
1+L2 10.71 (1)b 13.48 (2)b 3.87 2.77
1+L3 10.61 (2)b 13.26 (1)b 3.77 2.65
1+L4 11.02 (1)b 13.54 (1)b 4.18 2.52
a 25°C, 0.1 M phosphate buffer, pH 7.4, aqueous solution.
b 25°C, 0.1 M NaClO4, CH3CN solution; the standard deviations to the last signiﬁcant
ﬁgure are reported in parentheses.
Scheme 2. Reaction scheme for the system Cu(II) ion and glutathione; i–iii from Ref.
[41], iv from Ref. [45] and vi from Ref. [46].
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15 μMCC50 value for the Hep-G2 cell line; compoundswith phen usually
are more cytotoxic, in fact [Cu(phen)2(malonate)](ClO4)2 presents 3.8
and 0.8 μM CC50 values for the same cell lines, respectively [32].
3.4. Complex formation constants of Cu(II)–phen-L systems
The complex formation constants for the Cu(II)–phen and 1-L systems
were determined by spectrophotometric titration in the 400–1100 nm
region.
3.4.1. Cu(II)–phen system
In water solution at pH 7.4, 0.1 M phosphate buffer, only the spe-
cies [Cu(phen)]2+ and[Cu(phen)2]2+ could be spectrally studied, due
to the low solubility of the [Cu(phen)3]2+, species observed in CH3CN
solution [16]. The complex formation constants for the [Cu(phen)]2+
and [Cu(phen)2]2+ species are shown in Table 2.
3.4.2. 1-L systems
The UV–vis spectrophotometric titrations of 1 with the thionic li-
gands L1–L4 were carried out in CH3CN solution in 0.1 M NaClO4, due
to the low solubility of L1–L4 in water solution. The spectrum of the
blue 1 compound in CH3CN shows a peak at 670 nm, and, in analogy
with the blue complex [Cu(phen)3]2+ which shows a similar spectrum
with a peak at 675 nm, an octahedral coordination around the metal
Table 3
Complex formation constants for the system Cu(II)–phen-L1-GSH; the standard devia-
tions to the last signiﬁcant ﬁgure are reported in parentheses (25 °C, 0.1 M phosphate
buffer, pH 7.4, water solution).
Reactiona log β pK
[Cu(phen)]2++L3−⇌ [Cu(phen)(L)]− 14.49 (1) 6.35b
[Cu(phen)]2++2L3−⇌ [Cu(phen)(L)2]4− 18.93 (1) 4.44
[Cu(phen)]2++3L3−⇌ [Cu(phen)(L)3]7− 23.06 (1) 4.13
[Cu(phen)2]2++L3−⇌ [Cu(phen)2(L)]− 17.61 (1) 5.38c
[Cu(phen)2]2++2L3−⇌ [Cu(phen)2(L)2]4− 22.68 (3) 5.07
[Cu(phen)2(L1)]2++L3−⇌ [Cu(phen)2(L1)(L)]− 25.40 (2) 9.65d
a The values are expressed as association constants, glutathione is reported as L3−
(the real coordinating species) and not as HL2−, because the proton is not involved
in the reaction.
b Referred to the [Cu(phen)]2+ species.
c Referred to the [Cu(phen)2]2+ species.
d Referred to the [Cu(phen)2(L1)]2+ species.
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Fig. 3. Some spectra recorded during the titration of (A) 5.04×10−3 mmol of 1 (5.00 mL) with GSH, [GSH]=1.20×10−3 M, (B) 3.94×10−3 mmol of 2 (4.99 mL) with GSH, [GSH]=
1.05×10−3 M, (C) 9.96×10−4 mmol of C1 (6.00 mL) with GSH [GSH]=1.11×10−3 M, (D) 5.69×10−3 mmol of GSH (5.00 mL) with 2, [2]=3.25×10−4 M; l=1 cm, T=25 °C,
pH 7.4, 0.1 M phosphate buffer.
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ion may be hypothesized, such [Cu(phen)(CH3CN)4]2+. By adding 1
equivalent of the thionic ligands, the peak at 670 nm and its shoulder in-
creases in intensity; with the further addition of 1 equivalent of L, the
maximum shifts to higher wavelength and, at the end of the titration, a
peak appears at ≈760 nm with a shoulder at higher wavelengths. The
ﬁnal solution is green colored. The same behavior is observed for all
the ligands, due to the formation of two complexes with 1:1 and 1:2
Cu(II)/L molar ratios. The formation of these complexes and the
corresponding stoichiometry were also checked by the Job's method
[33]. In these two species, the penta-coordination around the metal
ion could be established by their spectra [16,34–37] and the formula
[Cu(phen)L(CH3CN)2]2+ and [Cu(phen)L2(CH3CN)]2+ may be hy-
pothesized. The complex formation constants for the 1-L systems are
reported in Table 2. The logK1 for the [Cu(phen)(L)(solv)2]2+ spe-
cies follows the substituent order: L1>L4>L2>L3, while the logK2
for the [Cu(phen)(L)2(solv)]2+ species follows the substituent order:
L1>L2>L3>L4.
3.5. Reactivity with GSH
The chemistry of the copper–glutathione system appears to be
controversial. In fact, some authors have studied the reactivity of
Cu(II) ions with GSH without considering or observing the reduction
of the metal ion [38,39], while some others have detected the reduc-
tion to Cu(I) and the formation of GSSG [40]. In most studies, the re-
duction of Cu(II) to Cu(I) and the oxidation of GSH to GSSG were
observed by a direct reaction between Cu(II) salts and GSH; EPR mea-
surements have provided evidence that the ﬁrst step of the overall pro-
cess is the formation of a transient complex between GSH and Cu(II),
with CuII(GS)2 stoichiometry (Scheme 2, eq. i). The lifetimes of these
species, together with their colors, varying from violet to red [41], are
strongly dependent on the pH of the medium [42,43]. In some cases,
the violet compound was attributed to a reversible reaction of a Cu(I)
complex with oxygen from the air [44]. With all these considerations,
it is clear that the system is particularly intricate, and that the involved
reactions depend onmany experimental variables. Summarizing the lit-
erature data, the reactions reported in Scheme 2 have been proposed
[41,45,46].
In contrast withmost of the studies, in which free Cu(II) ion plays the
lead role, we studied the reactivity of GSH with the Cu(II)-complexes 1,
2, and C1. In these species, the copper(II) oxidation state is stabilized
by the phen unit(s), as shown by the complex formation between 1
and 2 with L1–L4, which are able to reduce free Cu(II) ions in a very
fast reaction (this work and Ref. [16]).
Adding GSH to a buffered solution of complexes 1, 2, and C1
(10−3 M), the initial light blue solution readily turned a stable dark
blue–violet color with the formation of bands at ≈410 and 600 nm.
These bands can be ascribed to the formation of one or more Cu(II)
complexes with GSH and not to the reduction of Cu(II) to Cu(I). In
fact, [CuI(phen)]+ does not absorb in the visible region [47,48] and
[CuI(phen)2]+ is characterized by a peak at 435 nm and a broad band
at 530 nm.Moreover, under the chosen experimental conditions, no vis-
ible spectral changes occurred in the reaction of [CuI(phen)x]+ and GSH
or GSSG, nor with [CuII(phen)x]2+ and GSSG. To test the possibility that
the blue–violet species could be due to the reaction of some Cu(I) com-
plex with oxygen, as in eq. vi, we performed the experiments under an
Ar atmosphere, and we found that the formation of the blue–violet spe-
cies was even faster in absence of oxygen (S. I., Table S1). The different
results reported by other authors, as for example Gilbert [49], who
observed the formation of the Cu(I) complexes [CuI(phen)2]+ and
CuI(phen)(GS) in the reaction of [CuII(phen)2]2+ with GSH, might be
explained considering the different experimental conditions such as
the concentration of the buffer and/or reactants, which are particularly
critical in radical-involving reactions. Once veriﬁed that the redox reac-
tion of our systems with GSH under the chosen experimental conditions
was not observed, we studied the involved equilibria by spectrophoto-
metric titrations.
3.5.1. Complex formation constants for the systems 1, 2, and C1with GSH
Our studieswere carried out inwater solution at pH7.4 in 0.1 Mphos-
phate buffer; at this pH, GSH is present almost as a bis-deprotonated spe-
cies being the log of the dissociation constants 9.07 (cysteine -SH), 3.48
(glycine –COOH) and 2.3 (glutamyl –COOH) [11].
All the calculated complex formation constants for the studied
systems are shown in Table 3.
3.5.1.1. 1-GSH system. 5.04×10−3 mmol of 1 (5.00 mL)was titrated with
GSH (1.20×10−3 M). The solution spectrum of 1 (Fig. 3A) presents a
peak at 670 nm. With the addition of 1 equivalent of GSH, a band at
420 nm appears; with the addition of further 1 equivalent, two peaks
at 585 and 416 nm appear; and with the addition of the third equiva-
lent, the intensity of the spectra starts decreasing but with a different
proﬁle showing that at least three equilibria were present. The titration
data suggest the formation of three complexeswith the proposed stoichi-
ometry [Cu(phen)(GS)]−, [Cu(phen)(GS)2]4− and [Cu(phen)(GS)3]7− as
reported in Scheme 3.
3.5.1.2. 2-GSH system. 3.94×10−3 mmol of 2 (4.00 mL) was titrated
with GSH (1.05×10−3 M). The solution spectrum of 2 (Fig. 3B) pre-
sents two peaks at 720 and 950 nmwith a shape typical of an octahedral
coordinatedmetal ion [16,34–37]. By adding 1 equivalent of the GSH so-
lution, two bands appear at 414 and 584 nmwith an intensity ratio of
1.7; with the addition of the second equivalent of GSH, the band in-
tensities start decreasing with a different intensity ratio and proﬁle.
On the contrary, adding 1 equivalent of 2 to the GSH solution (5.69×
10−3 mmol, 5.00 mL, Fig. 3D), a convoluted band appears at 516 nm,
and with the addition of the second equivalent of 2, two more peaks
appear at 416 and604 nm. Increasing the amount of2 the three bands de-
crease in intensitywith thedilutionbutwithout proﬁle changes. Although
different species seemed to be formed in these two titrations, by decom-
position of the experimental bands into Gaussian primitives, all the spec-
tra could be ﬁttedwith the same parameters (four bands at 409, 502, 606,
Scheme 3. Reaction scheme for the systems 1, 2 and C1 with GSH*.
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and 833 nm), showing that the same species are present but in different
concentrations. Therefore, the experimental data of both the titrations
were ﬁtted simultaneously, conﬁrming the formation of two complexes,
[Cu(phen)2(GS)]− and [Cu(phen)2(GS)2]4− (Scheme 3). These two spe-
cies are characterized by similar spectra but with different absorptivity
values.
3.5.1.3. C1-GSH system. 9.96×10−4 mmol of C1 (6.00 mL) was titrat-
ed with GSH (1.11×10−3 M). By adding 1 equivalent of GSH to the
C1 solution (Fig. 3C), a [Cu(phen)2(L1)(GS)]− complex is formed; by
the addition of an excess of GSH, further spectral changes are evident
due to the formation of two complexes identiﬁed by their absorptivity
as [Cu(phen)2(GS)2]4− and [Cu(phen)(GS)3]7−, indicating that the
thionic ligand and a phen unit were removed from the coordination
sphere, (Scheme 3).
Complexes formed by 1, 2, or C1 with GSH present absorptivity
values typical of a charge-transfer transition (S.I., Table S2), while
the Cu(II)-GSSG species presents an absorptivity value (60 M−1 cm−1)
Scheme 4. Numbering sequence of GSH donor atoms and hypothesized coordination of GSH with 2.
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characteristic of a d–d electronic transition [45]. In particular, the band at
≈414 nm, present in all the spectra, has an absorptivity value typical of a
ligand-to-metal charge transfer transition (LMCT) and was assigned
using extended Huckel-type molecular orbital calculation, related to
the unpaired electron of Cu(II) ion [50]. The position of this band arises
from the ligand characteristics and allows the identiﬁcation of the type
of coordination, particularly for the sulfur-containing ligands; in fact, a
band in the 454–384 nm range is typical of a coordinating thiolate RS−
ligand [51]. The hypothesis that GSH could substitute a phen unit, as in
C1, was also proved by studying the reaction of 2 and 3 with GSH in
pure water. In fact, the same blue–violet compound was isolated in
both cases, and, from the ﬁltered solution of 3-GSH, white crystals of
phen were recovered. The elemental analysis of the obtained compound
gave the following percentages: C 53.27%, H 3.47%, and N 10.13%. The
copper content (9.95%) was determined by titration with EDTA. The IR
spectrumpresents awell-resolved peak at 1100 cm−1 of the perchlorate
anion and peaks at 630, 710, 850, 1450, and 1530 cm−1 due to the phen
ligands. No signal of the –SH group is present. This productwas also stud-
ied by transmission electronic microscopy (TEM) and PXRD. From the
TEMmeasurements (S.I., Fig. S2), information on themorphology and av-
erage size of the crystals was obtained, pointing out the presence of a
great number of crystallites with rod shapes. Any attempt to isolate a sin-
gle crystal suitable for X-ray analysiswas unsuccessful, and for this reason
we tested the crystalline nature of the particles by PXRD (S.I., Fig. S3), ver-
ifying in particular the absence of the pattern proﬁle of [CuI(phen)x]+,
CuI/CuII oxide, Cu0, or uncoordinated GSH (GSSG is amorphous). On the
basis of the tests and the elemental analysis, an unequivocal formula
could not be proposed, but at least three different hypotheses have to
be taken into account, i.e. the formation of the mononuclear complex i)
[Cu(phen)2(OH2)(GSH2)](ClO4), or the polynuclear complexes ii)
[(Cu(phen)2)2(H2O)(GS)](ClO4), or iii) [(Cu(phen)2)3(H2O)(GS)](ClO4)3.
As the –SH signal is missing in the I.R. spectrum, it is clear that the sulfur
atom participates in the coordination, then, in the presence of more than
one metal ion, carboxylate and amino groups are also involved in the co-
ordination as represented in Scheme 4 (the used numbering sequence of
donor atoms is also shown). For the species [Cu(phen)2(GSH2)](ClO4),
three isomers are possible (1–2, 4–5, and 1–5 coordinating atoms). All
the coordination modes were studied by quantomechanical methods.
Molecules as in i), ii), and iii) were built and their geometries were opti-
mized by semi-empirical methods using a PM3 basis set [52], with the
program SPARTAN'06 for Windows (Wavefunction Inc.). Molecules
with an octahedral coordination core around the copper(II) ion were
found to be the most stable. For ii), the isomer with 1–2 donor atoms
had the lowest enthalpy formation energy. The optimized geometry for
all the isomers and the corresponding formation enthalpies are reported
in the S. I. (Fig. S4); the most stable isomers are shown in Scheme 4.
3.6. Cyclic voltammetry experiments
Redox properties of 1, 2, 3, C1, and GSH were studied by cyclic
voltammetry (S.I., Fig. S5). Compounds 1, 2, and 3 are characterized
by two well-deﬁned cathodic peaks and at least one poorly resolved
anodic peak; while the peaks not detectable by direct examination of
the voltammogram were shown by derivative analysis. All the com-
pounds exhibit two one-electron potential waves belonging to the CuII/
CuI and CuI/Cu0 redox reactions (Ep (mV):−105 and 280 for 1, 10 and
146 for 2,−81 and 145 for 3,−25 for C1 and 300 for GSH). The redox
reactions of 1 appear to be quasi-reversible. The distance between the ca-
thodic peaks lowers passing from 1 to 2 and 3. The intensity of the two
cathodic peaks was comparable in 1, while the more negative peak di-
minishes in intensity passing to 2 and 3. In the voltammogram of C1,
only one cathodic peak is evident and an anodic peak is present at a
very high potential value. The GSH redox reaction appeared to be irre-
versible; in fact, only the reduction peak of GSSG was evident at each
cycle. As can be seen by analyzing the potential values, under the chosen
experimental conditions, copper(II) complexes are not reduced by GSH.
4. Conclusions
Copper(II) complexes with 1,10-orthophenanthroline (phen),
Cu(phen)(OH2)2(ClO4)2 (1), [Cu(phen)2(OH2)](ClO4)2 (2) and
[Cu(phen)3](ClO4)2 (3) were synthesized and the crystal structure of
1 was solved. Mixed complexes [Cu(phen)(L)]2+ (where L = N,N′-
substituted-imidazolidine-2-thione) were synthesized, and the com-
plex formation constants were evaluated. The cytotoxicity study of
[Cu(phen)2(L)]2+ was extended to four tumor cell lines, showing
good activity. The tested compounds are characterized by CC50 values
in the range of 1–3 μM for very deadly types of cancers such as squa-
mous lung cancer and prostate carcinoma. All complexes showed com-
parable inhibitory activities against both leukemia and carcinoma cells,
unlike the majority of antineoplastic agents which are usually markedly
more potent against hematologic cancer cells than solid tumor cells. The
insertion of the thionic ligands L on the core of 2 produced different ef-
fects on the corresponding cytotoxic activity towards the four tumor
cell lines, most probably because of the different hydrophilicity/lipophi-
licity of the resulting molecules. C3 and C4 derivatives, presenting the
lower dipole moment calculated values, are more active with solid can-
cer than with leukemia, while C1 and C2 derivatives, presenting the
higher dipolemoment values, aremore activewith hematological cancer
cells. The correspondence of the dipole moment and the kind of activity,
i.e. versus solid or liquid cancer cells, suggest that the choice of the sub-
stituents,which vary the lipophilicity/hydrophilicity,may play an impor-
tant role in the selection of the proper drug in the treatment of the cancer
cells. Although none of tested compounds emerged as a lead compound
in terms of anticancer potency, our results represent very promising pre-
liminary data. UV–vis and cyclic voltammetry experiments showed that
the Cu(II) ion in complexes 1, 2, 3, andC1 is not reduced by the tripeptide
glutathione GSHwhich acted as a coordinating ligand only. In particular,
as evidenced by spectrophotometric analysis, the 1-GSH system
leads to the formation of complexes with the proposed stoichiometry
[Cu(phen)(GS)]−, [Cu(phen)(GS)2]4−, and [Cu(phen)(GS)3]7−, where
GSH binds the Cu(II) via the thiolate sulfur atom. In the case of the
2-GSH system, the presence of two phen units crowding the copper
center allows the entry of only one or two GSH units to form the com-
plexes [Cu(phen)2(GS)]− and [Cu(phen)2(GS)2]4−. In the case of the
C1-GSH system, the complex [Cu(phen)2(L1)(GS)]− is formed; howev-
er, the substitution of L1with a GSH unit was only observed for C1/GSH
molar ratios higher than 1. An interesting stable blue–violet solid is
separated from the reaction of 3or2withGSH. The above reported exper-
imental data and the quantum mechanical calculations suggest the for-
mation of the mononuclear compound [Cu(phen)2(OH2)(GSH2)](ClO4)
or the polynuclear compounds [(Cu(phen)2)2(H2O)(GS)](ClO4) or
[(Cu(phen)2)3(H2O)(GS)](ClO4)3. Moreover, we have shown that under
our experimental conditions, reagent concentration, temperature, and
pH are important factors in driving the reaction towards either complex
formation or electron exchange.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jinorgbio.2012.04.017.
References
[1] J.R. Sorenson, Prog. Med. Chem. 26 (1989) 437–568.
[2] G. Psomas, A. Tarushi, E.K. Efthimiadou, Y. Sanakis, C.P. Raptopoulou, N. Katsaros,
J. Inorg. Biochem. 100 (2006) 1764–1773.
[3] F.Q. Liu, Q.Wang, K. Jiao, F. Jian, G. Liu, R. Li, Inorg. Chim. Acta 359 (2006) 1524–1530.
[4] D.S. Sigman, A. Mazumder, D.M. Perrin, Chem. Rev. 93 (1993) 2295–2316.
[5] C. Dendrinou-Samara, G. Psomas, C.P. Raptopoulou, D.P. Kessissoglou, J. Inorg.
Biochem. 83 (2001) 7–16.
[6] B.K. Santra, P.A.N. Reddy, G. Neelakanta, S. Mahadevan, M. Nethaji, A.R. Chakravartym,
J. Inorg. Biochem. 89 (2002) 191–196.
[7] L.Z. Li, C. Zhao, T. Xu, H. Ji, Y. Yu, G. Guo, H. Chao, J. Inorg. Biochem. 99 (2005)
1076–1082.
36 T. Pivetta et al. / Journal of Inorganic Biochemistry 114 (2012) 28–37
[8] I. Gracia-Mora, L. Ruiz-Ramírez, C. Gómez-Ruiz, M. Tinoco-Méndez, A. Márquez-
Quiñones, L. Romero-De Lira, A. Marín-Hernández, L. Macías-Rosales, M.E. Bravo-
Gómez, Met.-Based Drugs 8 (2001) 19–28.
[9] R. Alemon-Medina, M. Brena-Valle, J.L. Munoz-Sanchez, M.I. Gracia-Mora, L.
Ruiz-Azuara, Cancer Chemother. Pharmacol. 60 (2007) 219–228.
[10] F. Carvallo-Chaigneau, C. Trejo-Solis, C. Gomez-Ruiz, E. Rodriguez-Aguilera, L.
Macias-Rosales, E. Cortes-Barberena, C. Cedillo-Pelaez, I. Gracia-Mora, L. Ruiz-
Azuara, V. Madrid-Marina, Biometals 21 (2008) 17–28.
[11] A. Corazza, I. Harvey, P.J. Sadler, Eur. J. Biochem. 236 (1996) 697–705.
[12] I. Jimenez, P. Aracena, M. Letelier, P. Navarro, H. Speisky, Toxicol. In Vitro 16 (2002)
167–175.
[13] M. Letelier, A.M. Lepe, M. Faundez, J. Salazar, R. Marin, P. Aracena, H. Speisky,
Chem. Biol. Interact. 151 (2005) 71–82.
[14] R.N. Bose, S. Moghaddas, E.L. Weaver, E.H. Cox, Inorg. Chem. 34 (1995) 5878–5883.
[15] E.M. Kosower, in: I.M. Arias, E.B. Jakoby (Eds.), Glutathione: Metabolism and
Function, Raven Press, New York, 1976, p. 1.
[16] T. Pivetta, M.D. Cannas, F. Demartin, C. Castellano, S. Vascellari, G. Verani, F. Isaia,
J. Inorg. Biochem. 105 (2011) 211–220.
[17] F.J.C. Rossotti, H. Rossotti, The Determination of Stability Constants, McGraw-Hill,
1961.
[18] M. Meloun, J. Havel, E. Högfeldt, Computation of Solution Equilibria — A Guide to
Methods in Potentiometry, Extraction and Spectrophotometry, Ellis Horwood,
Chichester, 1988 297 pages, ISBN 0-7458-0201-X.
[19] A. Ringbom, J. Chem. Educ. 35 (6) (1958) 282–288.
[20] P. Gans, A. Sabatini, A. Vacca, Talanta 43 (1996) 1739–1753.
[21] C.F. Macrae, P.R. Edgington, P. McCabe, E. Pidcock, G.P. Shields, R. Taylor, M.
Towler, J. van de Streek, J. Appl. Crystallogr. 39 (2006) 453–457.
[22] R. Pauwels, J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyster, E.
De Clercq, J. Virol. Meth. 20 (1988) 309–321.
[23] SADABS Area-detector Absorption Correction Program, Bruker AXS Inc., Madison,
WI, USA, 2000.
[24] A. Altomare, M.C. Burla, M. Camalli, G.L. Cascarano, C. Giacovazzo, A. Guagliardi,
A.G.G. Moliterni, G. Polidori, R. Spagna, J. Appl. Crystallogr. 32 (1999) 115–119.
[25] G.M. Sheldrick, Acta Crystallogr. A64 (2008) 112–122.
[26] L.J. Farrugia, J. Appl. Crystallogr. 32 (1999) 837–838.
[27] K. Kaabi, M. El Glaoui, M. Zeller, C.B. Nasr, Acta Crystallogr. E Struct. Rep. Online
(2010) m1145–m1146.
[28] J. Janiak, J. Chem. Soc., Dalton Trans. (2000) 3885–3896.
[29] M. Damous, M. Hamlaoui, S. Bouacida, H. Merazig, J.C. Daran, Acta Crystallogr. E67
(2011) m611–m612.
[30] G. Murphy, C. Murphy, B. Murphy, B. Hathaway, J. Chem. Soc., Dalton Trans. (1997)
2653–2660.
[31] A. Leo, C. Hansch, D. Elkins, Chem. Rev. 71 (1971) 525–616.
[32] C. Deegan, M. McCann, M. Devereux, B. Coyle, D.A. Egan, Cancer Lett. 247 (2007)
224–233.
[33] P. Job, Ann. Chim. (Paris) 9 (1928) 113–203.
[34] J. Foley, D. Kenneﬁck, D. Phelan, S. Tyagi, B. Hathaway, J. Chem. Soc., Dalton Trans.
(1983) 2333–2338.
[35] B.J. Hathaway, D.E. Billing, Coord. Chem. Rev. 5 (1970) 143–207.
[36] Z.L. Lu, C.Y. Duan, Y.P. Tian, X.Z. You, X.Y. Huang, Inorg. Chem. 35 (1996) 2253–2258.
[37] A.W. Addison, T.N. Rao, J. Reedijk, J. Van Rijn, G.C. Verschoor, J. Chem. Soc., Dalton
Trans. (1984) 1349–1356.
[38] P.W. Albro, J.T. Corbett, J.L. Schroeder, J. Inorg. Biochem. 27 (1986) 191–203.
[39] B. Jezowska-Trzebiatowska, G. Formicka-Kozlowska, H. Kozlowski, J. Inorg. Nucl.
Chem. 39 (1977) 1265–1268.
[40] M.R. Ciriolo, A. Desideri, M. Paci, G. Rotilio, J. Biol. Chem. 265 (1990) 11030–11034.
[41] N.D. Yordanov, Trans. Met. Chem. 22 (1997) 200–207.
[42] E.W. Ainscough, A.G. Bingham, A.M. Broide, Inorg. Chim. Acta 138 (1987) 175–177.
[43] J.M. Downes, J. Whelan, B. Bosnich, Inorg. Chem. 20 (1981) 1081–1086.
[44] B. Loeb, I. Crivelli, C. Andrade, Inorg. Chim. Acta 231 (1995) 21–27.
[45] W.S. Postal, E.J. Vogel, C.M. Young, F.T. Greenaway, J. Inorg. Biochem. 25 (1985) 25–33.
[46] H. Speisky, M. Gomez, F. Burgos-Bravo, C. Lopez-Alarcon, C. Jullian, C. Olea-Azar,
M.E. Aliaga, Bioorg. Med. Chem. 17 (2009) 1803–1810.
[47] G.F. Smith, Anal. Chem. 26 (1954) 1534–1538.
[48] R.T. Pﬂaum, W.N. Brandt, J. Am. Chem. Soc. 72 (1955) 2019–2022.
[49] B.C. Gilbert, S. Silvester, P.H. Walton, J. Chem. Soc., Perkin Trans. 2 (1999) 1115–1121.
[50] B.J. Hathaway, in: G. Wilkinson, R.D. Gillard, J.A. McCleverty (Eds.), Comprehen-
sive Coordination Chemistry, vol. 5, Pergamon, Oxford, 1987, p. 679.
[51] E.I. Solomon, K.W. Penﬁeld, D.E. Wilcox, Struct. Bond. (Berlin) 53 (1983) 1–57.
[52] J.J.P. Stewart, J. Comput. Chem. 10 (1989) 209–220.
37T. Pivetta et al. / Journal of Inorganic Biochemistry 114 (2012) 28–37
Development and validation of a general approach to predict and quantify the
synergism of anti-cancer drugs using experimental design and artiﬁcial
neural networks
Tiziana Pivetta a,n, Francesco Isaia a, Federica Trudu a, Alessandra Pani b, Matteo Manca b, Daniela Perra b,
Filippo Amato c, Josef Havel c,d,e
a Chemical and Geological Sciences Department, University of Cagliari, 09042 Monserrato (CA), Italy
b Biomedical Sciences Department, University of Cagliari, 09042 Monserrato (CA), Italy
c Department of Chemistry, Faculty of Science, Masaryk University, Kampus Bohunice, Kamenice 5/A14, 62500 Brno, Czech Republic
d Department of Physical Electronics, Masaryk University, Kotlářská 2, 611 37 Brno, Czech Republic
e R&D Center for Low-cost PLasma and Nanotechnology Surface Modiﬁcations, Faculty of Science, Masaryk University, Kotlářská 2, 611 37 Brno, Czech Republic
a r t i c l e i n f o
Article history:
Received 8 January 2013
Received in revised form
9 April 2013
Accepted 12 April 2013
Available online 18 April 2013
Keywords:
Artiﬁcial neural networks
Cancer
Cisplatin
Copper complexes
Experimental design
Synergism
a b s t r a c t
The combination of two or more drugs using multidrug mixtures is a trend in the treatment of cancer. The
goal is to search for a synergistic effect and thereby reduce the required dose and inhibit the
development of resistance. An advanced model-free approach for data exploration and analysis, based
on artiﬁcial neural networks (ANN) and experimental design is proposed to predict and quantify the
synergism of drugs. The proposed method non-linearly correlates the concentrations of drugs with the
cytotoxicity of the mixture, providing the possibility of choosing the optimal drug combination that gives
the maximum synergism. The use of ANN allows for the prediction of the cytotoxicity of each
combination of drugs in the chosen concentration interval. The method was validated by preparing
and experimentally testing the combinations with the predicted highest synergistic effect. In all cases,
the data predicted by the network were experimentally conﬁrmed.
The method was applied to several binary mixtures of cisplatin and [Cu(1,10-orthophenanthroli-
ne)2(H2O)](ClO4)2, Cu(1,10-orthophenanthroline)(H2O)2(ClO4)2 or [Cu(1,10-orthophenanthroline)2(imida-
zolidine-2-thione)](ClO4)2. The cytotoxicity of the two drugs, alone and in combination, was determined
against human acute T-lymphoblastic leukemia cells (CCRF-CEM). For all systems, a synergistic effect was
found for selected combinations.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
Nowadays, a trend in the treatment of cancer is to combine the
effects of several drugs using multidrug mixtures in order to reduce
the required dose and to slow the onset of drug resistance. A
combination of two or more drugs might show different effects
with respect to those of the individual drugs. When no difference
occurs, it means that the action of one drug is not inﬂuenced by
the action of the other drugs, and the global effect is due to their
individual activities. Otherwise, when a difference occurs, this can
be either negative or positive; in the former case, the drugs act
antagonistically, while in the latter synergistically. Then, the
deﬁnition of the pure additive effect of the combined drugs is
the reference point to understand if the biological activity of a
multidrug mixture is due to synergism or antagonism. This
deﬁnition has been proposed and interpreted by various authors
[1–7] with different methods to search for synergy. The most
common deﬁnitions are based on the combination index (CI) or
isobologram (IB) methods. In particular, today, CI is the most
commonly used method. In our opinion, this approach has limited
applicability because it is based on the assumption that the action
of the drugs is due only to the inhibition of enzyme kinetics [4]. In
fact, a model introduced in 1984 [8] and based on this idea is still
proposed for the interpretation of experimental data. However, it
is now well-known that in addition to enzymatic inhibition, drug-
receptor and non-speciﬁc interactions are also involved. Therefore,
a modern model should consider the entire complexity of the
phenomena occurring within the cell. Cisplatin (CDDP) is an
example of drug that does not act directly on enzyme kinetics.
In fact, it kills cancer cells by binding to their nuclear DNA [9,10],
distorting its structure and triggering cellular processes that result
in apoptosis [11]. Therefore, experimental data should be analyzed
using approaches that are more general than CI or IB.
Contents lists available at SciVerse ScienceDirect
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Models based on the physico-chemical description of the
processes occurring in a system are usually called hard. However,
because of the lack of knowledge on all the possible interactions
among drugs and the constituents and/or the biochemical pro-
cesses involved within the cell, this kind of model is incomplete
and therefore limited. In fact, the CI and IB methods are neither
able to quantify nor to predict the cytotoxicity of a given
combination of studied drugs. Therefore, the features of such
models limit their general applicability and sometimes lead to
contradictory results. For all these reasons, we suggest a different
way of thinking.
Let us consider the concentrations of the drugs in the mixture
as input variables while cytotoxicity as a response or output one.
The values of the response variable for all the possible combina-
tions of the input variables form the response surface. The value of
the response depends upon all the processes or phenomena that
occur in the system and are reﬂected in the shape of the response
surface. Therefore, building a model of the response surface means
to build a model of the whole system's behavior. As a consequence,
the response for all the possible values of the input variables can
be estimated or predicted. The model can be built by soft methods
which do not require any assumptions. Polynomial ﬁtting, multiple
linear regression (MLR) and partial least squares are examples of
common soft methods. However, several of them suffer of some
limitations [12].
Artiﬁcial neural networks (ANN) represent a powerful mathe-
matical tool able to accomplish a learning process using a set of
experimental data (training set) and to generalize this knowledge
to predict the response. Then, the ANN can understand the
unknown relationship existing among the input and the response
variables. The network learns by extracting the information hidden
in the experimental data of the training set. The choice of the
experimental data is crucial for good results, and, for practical
reasons, the number of experiments should be as low as possible
while providing a high content of information. This can be
achieved by using experimental design (ED) techniques [13].
The aim of this work is to: (i) generalize in a rigorous
mathematical form the deﬁnition of the pure additive effect of
an arbitrary number of drugs, (ii) develop an original approach for
the evaluation of cytotoxicity data with which to search for the
optimal drug combination that gives the maximum synergism and
(iii) apply the proposed approach to evaluate the occurrence of
synergism in a series of binary mixtures of CDDP and three
different complexes of copper(II) with 1,10-ortho-phenanthroline
(phen) against a human acute T-lymphoblastic leukemia cell line
(CCRF-CEM). The chosen complexes, Cu(1,10-orthophenanthroline)
(H2O)2(ClO4)2 (1), [Cu(1,10-orthophenanthroline)2(H2O)](ClO4)2
(2) and [Cu(1,10-orthophenanthroline)2(imidazolidine-2-thione)]
(ClO4)2 (C1), show antitumor effects both in vitro and in vivo [14]
and high cytotoxic activity against mouse neuroblastoma, human
hematologic and also solid tumor-derived cell lines [15,16]. The
proposed approach was validated and tested. The results were
achieved using an advanced approach of data exploration and
analysis, based on ANN and ED. A comparison with the traditional
methods, IB and CI, is also given. The results obtained with the
proposed method are compared with those obtained by MLR. The
results of the mass spectrometric analysis of the studied mixtures
are also given and discussed.
2. Theoretical aspects of the proposed approach
2.1. Generalized deﬁnition of additive effect
Starting from the simple deﬁnition of the additive effect of two
drugs proposed by Webb and Bliss [17,18], we developed a general
deﬁnition for any number of drugs. The additive effect of drugs is
not the algebraic summation of their cytotoxic activities. For this
reason, the expression “non-algebraic additive effect” (NAAE) will
be used in this work in place of “additive effect”.
Given n drugs (with n≥2) with individual percentage of
mortality values (number of dead cells with respect to the
controls) a1, a2, …, an, (with ai≥0), the NAAE is expressed for each
drug combination in generalized form as:
NAAE¼ ∑
n
i ¼ 1
ai þ ∑
n
k ¼ 2
ð  1Þk1Cn;k a1 ; a2 ; :::; anf g
100k1
h i
ð1Þ
where Cn,k{a1, a2, …, an} are the simple combinations without
repetition of the cytotoxicity values of the n drugs taken k at a
time (with k≥2). The set of the values given by Eq. (1) has 0% and
100% as the lower and upper limits, respectively, because no
mixture of drugs can have an effect greater than 100% and/or
lower than 0%. The NAAE as expressed by Eq. (1) represents a new
operational deﬁnition of the additive effect. It is calculated
according to a sequential action of the drugs and does not need
to be justiﬁed on a biochemical basis.
The expanded form of Eq. (1) is given by Eq. (2), where each
term in square brackets accounts for n!/[k!(n−k)!] elements.
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For two drugs, Eq. (2) assumes the same form (Eq. (3)) of the
equation proposed by Webb and Bliss [17,18].
NAAE¼ a1 þ a2−
a1a2
100
ð3Þ
For three drugs, Eq. (2) becomes Eq. (4).
NAAE¼ a1 þ a2 þ a3−
a1a2 þ a1a3 þ a2a3
100
þ a1a2a3
1002
ð4Þ
The deﬁnition of NAAE given by Eq. (1) is the reference point
which allows us to deﬁne the occurrence of synergism or antag-
onism of drugs. This is done by calculating the net multi-drug
effect index (NMDEI) as in Eq. (5), where Eexp. is the experimental
antiproliferative effect of a given drug combination.
NMDEI ¼ Eexp:−NAAE ð5Þ
NMDEI gives a quantitative account of the net multidrug effect
and can assume either positive or negative values that indicate
synergism or antagonism, respectively. When NMDEI is equal to
zero, then the experimental activity of the multidrug mixture is
equal to NAAE (Eq. (5)). Since the cytotoxic activity of an individual
drug and/or that of a drug combination is expressed as a
percentage, NAAE and NMDEI are also expressed as a percentage.
Using the proposed ED–ANN combined approach, the cytotoxi-
city of individual drugs and that of their combinations at concen-
trations not experimentally tested can be predicted on the whole
working space using a grid with desired dimensions. The values
estimated for each point of the chosen grid in place of the
experimental values (Eexp.) can be used in Eq. (5). The cytotoxicity
values of individual drugs (ai) estimated by the network compose
their related dose–response curves. Using such curves, the NAAE
can be calculated for each point of the grid. Then, the NMDEI can
be calculated according to Eq. (5) for each point of the chosen grid.
2.2. Artiﬁcial neural networks
An ANN is a formal object that emulates the structure of the
brain and its learning ability [13]. A series of logic units, called
neurons, is organized in layers: input, hidden and output. An
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example of the ANN architecture used in this work is given in the
supplementary materials (Fig. S1).
As for the biological brain, an ANN needs to be trained before it
can be used for prediction. This is done using a training set formed
by known input-response data. The inputs are iteratively pro-
cessed by the network according to a suitable training algorithm in
order to estimate the actual output of the training set. Several
algorithms are available [19], for example standard back-
propagation [20], R-propagation [21] and quick-propagation [22].
The root mean square error (RMSE) is calculated according to Eq.
(6), where N, M, opk, and o
ðnÞ
pk are the number of experiments used
for training, the number of response variables, the estimated and
the actual output value, respectively.
RMSE¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
N
p ¼ 1
∑
M
k ¼ 1
ðopk  opkÞ2
N M
vuuut
ð6Þ
The available data set is usually divided into three subsets:
(i) training, (ii) veriﬁcation and (iii) the test set. The veriﬁcation set
is used during training to monitor the generalization ability of the
network. Training is stopped when the minimum RMSE for the
veriﬁcation set is reached. Once the network is trained and
veriﬁed, it should be validated. This is done in the so-called test
step by comparing the estimated and experimental response for
selected input data.
2.3. Response surface and experimental design
The working space is the plane delimited by the minimum and
maximum values of the chosen variables. For example, let us
consider the concentration of drug A (CA) as the x-axis, while that
of drug B (CB) as the y-axis. Supposing p≤CA ≤q and r ≤CB ≤s, the
working space is given by all the points w belonging to the set W
deﬁned by Eq. (7).
W ¼ w=w¼ ðCA;CBÞ∈R=p≤CA≤q∧r≤CB ≤s
  ð7Þ
Therefore, each point w belonging to W represents the condi-
tions of one experiment. The response variable z (e.g. cytotoxicity)
is a function of the chosen CA and CB variables (Eq. (8)).
z¼ f ðwÞ ¼ f ðCA;CBÞ ð8Þ
The set Z given by Eq. (9) deﬁnes the response surface.
Z ¼ z=z¼ f ðwÞ;w∈W  ð9Þ
The aim of hard modeling is ﬁnding out the analytical expres-
sion of the function f according to a rigorous physical description
of the studied system. However, f is often very complex or even
unknown. Therefore, the function f can be approximated employ-
ing soft modeling. Each point w provides information about the
function f. A greater number of experiments is associated with a
better model. However, the duration and the cost of the experi-
ments are often crucial. Then, a compromise to obtain an accep-
table model with the lowest number of experiments is needed. ED
is a chemometrical tool used to distribute n experiments on the
working space in such a way that the information content for that
n is the highest [23]. For the study of drug combinations, as a ﬁrst
approach, the concentrations of the drugs should be chosen in the
range within 0 and twice the CC50 (the dose of the drug which
inhibits 50% of cell proliferation). Therefore, knowledge of a simple
estimation of CC50 is needed.
For the evaluation of the cytotoxic activity of two or more
drugs, the following information is necessary:
– a sufﬁcient number of experiments to model the dose–response
curve of each drug;
–
a sufﬁcient number of experiments distributed in the studied
space to model the cytotoxicity response surface.
Due to the assay techniques of the cytotoxic activity, a non-
symmetrical experimental design was used here. However, the
lack of symmetry of the experimental design does not affect the
performance of the chosen method that has been shown to
properly describe the studied systems.
The chosen experimental designs are shown in Fig. 1a, c and e.
The points used in the training, validation and test sets are
highlighted in Figs. 1–4 and S3–S6.
2.4. Structure of the proposed approach
The proposed ED–ANN approach consists of the following
steps:
(1) Set-up of the ED.
(2) Experimental determination of the cytotoxicity of the drugs
alone and those of the multidrug mixtures prepared according
to the chosen ED.
(3) Training and veriﬁcation of the artiﬁcial neural network.
(4) Prediction of the response using the network, according to a
suitable grid that covers the entire working space.
(5) Calculation of the NAAE for each point of the grid.
(6) Calculation and plot as a function of the drug concentrations of
NMDEI (NMDEI surface).
(7) Testing the obtained results.
3. Materials and methods
3.1. Reagents
Copper(II) carbonate basic (Cu2(CO3)(OH)2), 1,10-phenanthro-
line monohydrate, cisplatin (CDDP), perchloric acid, ethanol, ethyl
ether, dimethyl sulfoxide (DMSO), imidazolidine-2-thione,
3-hydroxy picolinic acid, acetonitrile (CH3CN), trypan blue and
6-mercaptopurine were purchased from Sigma-Aldrich (Milan,
Italy) and used without any further puriﬁcation. Fetal calf serum
(FCS), penicillin G sodium and streptomycin sulfate were pur-
chased from Gibco-Invitrogen (Milan, Italy) and used without any
further puriﬁcation. Red phosphorus was purchased from Riedel
de Haën (Hannover, Germany). Water was double distilled from a
quartz apparatus from Heraeus Quarzschmelze (Hanau, Germany).
3.2. Synthesis
The compounds 1, 2 and C1 were prepared as previously
reported [15,16]. Brieﬂy, copper perchlorate was prepared in situ
by the reaction of Cu2(CO3)2(OH)2 with HClO4 in a 1:2 M ratio in
ethanol solution; phen was added in a Cu(II):phen molar ratio of
1:1 or 1:2 to obtain 1 or 2, respectively. C1 was prepared by the
reaction of 2 and imidazolidine-2-thione in a 1:1 M ratio in CH3CN
solution.
3.3. Cell lines
The CCRF-CEM (acute T-lymphoblastic leukemia) human cell
line was purchased from the American Type Culture Collection
(ATCC-LGC; Milan, Italy). The cell line was grown at 37 1C in a 5%
CO2 atmosphere in RPMI 1640 medium according to instructions
from ATCC in the presence of 10% FCS, 100 U/mL penicillin and
100 μg/mL streptomycin. The cell line was maintained in
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exponential growth by periodically splitting high density suspen-
sion cultures (i.e. 106/mL). The cell culture was periodically tested
for the absence of mycoplasma contamination.
3.4. Cytotoxic assay
The cytotoxic effect of test compounds was evaluated in
exponentially growing cell cultures. Stock solutions of test com-
pounds were made at 1 mM in DMSO and stored at 4 1C in the
dark. For the evaluation of cytotoxicity, each compound was
serially diluted in speciﬁc growth medium so that the concentra-
tion of DMSO was never higher than 0.1%. Cell growth in the
absence and in the presence of the test compounds was deter-
mined after 96 h of incubation, corresponding to three duplication
rounds of untreated cells, by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) method [24]. Numbers of
viable cells were also determined by the trypan blue dye exclusion
method. Cell growth at each drug concentration was expressed as
the percentage of untreated controls. Each compound was tested
in at least three independent assays. Statistical analysis was
Fig. 1. Experimental design (■ training set, ☆ validation set and ○ test set) for the systems (a) 1-CDDP, (c) 2-CDDP and (e) C1-CDDP; comparison between experimental (■
training set, ☆ validation set and ○ test set) and calculated mortality values for the systems (b) 1-CDDP, (d) 2-CDDP and (f) C1-CDDP (linear ﬁtting parameters for the
equation y¼mX are m¼0.999(3) with r¼0.9999 for the training set, m¼1.00(1) and r¼0.9986 for the validation set, m¼0.990(1) and r¼0.9995 for the test set, m¼1.00
(1) and r¼0.9993 for all the data values for 1-CDDP; m¼1.00(1) with r¼0.9991 for the training set, m¼0.99(1) and r¼0.9978 for the validation set, m¼1.00(1) and
r¼0.9988 for the test set, m¼1.00(1) and r¼0.9988 for all the data values for 2-CDDP; m¼1.00(1) with r¼0.9991 for the training set, m¼1.00(1) and r¼0.9995 for the
validation set, m¼1.08(2) and r¼0.9977 for the test set, m¼1.02(1) and r¼0.9988 for all the data values for C1-CDDP.
T. Pivetta et al. / Talanta 115 (2013) 84–93 87
performed with Student's t-test, and signiﬁcance was set at
p≤0.05. The antitumor agent 6-mercaptopurine was used as a
reference compound. Because of the variability in cell reactivity
(correlated to the growing time and the ﬁnal density of the
suspension cultures) slight differences were observed in the
cytotoxicity values of CDDP obtained in these experiments.
3.5. Mass spectrometry
Mass spectra were recorded using AXIMA Resonance mass
spectrometer from Kratos Analytical (Manchester, UK), equipped
with a quadruple ion trap (QIT) and a reﬂectron time-of-ﬂight
analyzer (RTOF). The instrument for drying samples was from
Kratos Analytical. Calibration was done using red phosphorus
clusters as described in [25].
Laser desorption ionization (LDI) and matrix-assisted laser-
desorption ionization (MALDI) were used. From several matrices
examined, 3-hydroxo picolinic acid was found to be the most
suitable. It was found that all the species detected both in LDI and
MALDI analyses were singly charged. The mixtures of 1, 2 and C1
complexes with CDDP (5:1 molar ratio) were prepared in 50%
acetonitrile/water. For LDI analysis, 5 μL of the mixture were
deposited on the metallic target of the instrument and, after
drying, the mass spectra were recorded. For MALDI analysis, ﬁrst
5 μL of saturated solution of matrix were deposited and, after
drying, 5 μL of the mixture were deposited on the matrix layer and
dried again.
Mass spectra were recorded in both reﬂectron positive and
negative ion mode after the pressure was below 10−4 Torr. Mass
spectra recorded in negative ion mode were found to be not
suitable, therefore only mass spectra recorded in positive ion
mode were used.
3.6. Software
ANN computation was performed using the Trajan Neural
Network Simulator (release 3.0 D, Trajan Software, Horncastle,
UK) and EasyNN-plus (Neural Planner Software Ltd, Cheadle
Hulme, UK) programs. All computations were performed on a
standard PC computer with Microsoft Windows XP Professional as
operating system. Other mathematical calculations were done
using GNU Octave ver. 3.2.4 (Free Software Foundation, Inc.
http://fsf.org/) conﬁgured for i686-pc-linux-gnu on a standard PC
x86 running Ubuntu Linux ver. 12.04.
4. Results and discussion
4.1. Set up of the ED
For each binary mixture, the experimental design was built
choosing the concentration interval of the drugs in the range 0
−∼2CC50. Following the experimental design reported in Fig. 1a,
42 combinations of 1 and CDDP, nine solutions of CDDP alone and
nine solutions of 1 alone were prepared. Among the 60 solutions,
25 were used as the training set, 24 as the validating set and 11 as
the test set. Following the experimental design reported in Fig. 1c,
34 combinations of 2 and CDDP, six solutions of CDDP alone and
four solutions of 2 alone were prepared. Among the 44 solutions,
18 were used as the training set, 16 as the validating set and 10 as
the test set. Following the experimental design reported in Fig. 1e,
33 combinations of C1 and CDDP, seven solutions of CDDP alone
and ﬁve solutions of C1 alone were prepared. Among the 46
solutions, 21 were used as the training set, 19 as the validating set
and six as the test set. The test sets for all the systems were chosen
after the inspection of the results obtained by the network.
4.2. Experimental determination of the cytotoxicity of individual
drugs and multidrug mixtures prepared according to the chosen ED
Three different sets of experiments were carried out, each one
in three replicates, for the 1-CDDP, 2-CDDP and C1-CDDP combi-
nations. The concentration of 1 was in the range of 0–5 μM, while
the concentrations of 2, C1 and CDDP were in the range of 0–2 μM.
The vitality (% of living cells) after the treatment with the drugs
was measured for each solution with respect to the control
(untreated cells) and converted into mortality (100% minus
vitality).
4.3. Training and veriﬁcation of the artiﬁcial neural network
The concentrations of the drugs and the experimental cyto-
toxicity values were used as the input and output data. As the
training algorithm, standard back-propagation [20] was used.
At ﬁrst, the optimal neural network architecture was searched
for using the criteria of lowest RMSE. The number of hidden layers
and the number of neurons therein were investigated. The value of
RMSE for the training and veriﬁcation sets were plotted against the
number of neurons in the hidden layers. The optimal number of
Fig. 2. Response surface with experimental data (■ training set, ☆ validation set
and ○ test set) (a) and contour plot of cytotoxicity iso-values (b) for the system 1-
CDDP.
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neurons is found when the minimum RMSE for the veriﬁcation set
is reached. It was found that a three-layer structure, i.e. one input,
one hidden and one output, with four (for 1-CDDP and C1-CDDP)
or ﬁve (for 2-CDDP) neurons in the hidden layer was sufﬁcient.
The network's parameters were re-initialized several times, ran-
domly changing their initial values to prove the robustness of the
model and the reproducibility of the results. The resulting archi-
tecture of the network for the C1-CDDP system is shown in Fig. S1
as an example.
For each system, the network was trained and veriﬁed using
the proper training and validation sets. All points lying on the
borders of the experimental design were included in the training
set. Validation points were chosen randomly on the working
space. The training was stopped when the minimum RMSE for
veriﬁcation step was reached (the plot of RMSE vs. number of
epochs for the system 1-CDDP is shown as an example in Fig. S2).
The agreement between the values calculated by the network and
the experimental ones is shown in Fig. 1b, d, f, where the
calculated and experimental data are plotted against each other.
Once trained and veriﬁed, the network was used to predict the
cytotoxicity on the whole working space according to a grid with
dimensions 4040.
4.4. Exploring the response surface
The plot of the calculated cytotoxicity values as a function of
the concentration of the drugs represents the response surface.
The response surface and related contour plot for 1-CDDP system
is shown in Fig. 2. The results for 2-CDDP and C1-CDDP systems
are shown in Figs. S3 and S4. The mortality of the mixtures
increases proportionally with the concentrations of the two drugs
(Fig. 2a, S3a and S4a). The resulting surface shows similar trend to
that of the dose–response curve.
Using the contour plot (Fig. 2b, S3b and S4b), the areas of
cytotoxicity iso-values for the various mixtures can be explored. In
this way, the mixture with the desired cytotoxicity and the related
lowest dose of both drugs can be found. In fact, for a toxicity of
70%, instead of choosing 1 alone at a concentration of ≈3.5 μM, 2
alone at ≈1.5 μM, C1 alone at ≈1.4 μM or CDDP alone at a ≈1.2 μM,
it is possible to select appropriate combinations such as:
- 1 at 2.0 μM and CDDP at 0.78 μM (Fig. 2b)
- 2 at 0.9 μM and CDDP at 0.95 μM (Fig. S3b)
- C1 at 0.65 μM and CDDP at 0.60 μM (Fig. S4b)
For a toxicity of 50%, instead of choosing 1 alone at a
concentration of ≈3 μM, 2 alone at ≈1.25 μM, C1 alone at ≈1 μM
or CDDP alone at ≈1 μM, it is possible to select:
- 1 at 1.88 μM and CDDP at 0.60 μM (Fig. 2b)
- 2 at 0.75 μM and CDDP at 0.80 μM (Fig. S3b)
- C1 at 0.50 μM and CDDP at 0.45 μM (Fig. S4b).
The use of a lower concentration of each drug minimizes the
side effects related to the doses. The reliability of the network and
of the obtained results is shown by the good agreement between
the calculated and experimental values, as can be seen in Fig. 2a,
S3a and S4a, where the experimental points are superimposed on
the calculated surfaces.
From the calculated cytotoxicity values of the bottom and left
borders of the ED (i.e. for a single drug at time) the dose–response
curves for 1, 2, C1 and CDDP is obtained. In Fig. 3a–d, the
calculated curves are shown together with the experimental
Fig. 3. Calculated (--) and experimental (■) dose–response data for (a) 1, (b) 2, (c) C1 and (d) CDDP against the CCRF-CEM cell line.
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points. For 1, 2 and C1, a sigmoidal curve was obtained. The
threshold doses (the minimum dose at which the drug presents an
effect) for 1, 2, C1 and CDDP are 1 μM, 0.5 μM, 0.25 μM and
0.375 μM, respectively. The calculated CC50 values are in the order:
CDDP (0.922 μM)<C1(0.989 μM)<2(1.26 μM)⪡1 (3.01 μM).
4.5. Calculation of the NAAE and the NMDEI surface
The NAAE was calculated according to Eq. (1) and subtracted
from the cytotoxicity values for all the points of the used grid to
determine the NMDEI (Eq. (5)). The plot of the NMDEI as a function
of the drug concentrations and the related contour plot is shown
in Fig. 4 for 1-CDDP system. The results for 2-CDDP and C1-CDDP
systems are shown in Figs. S5 and S6. Only positive values of
NMDEI are present for the 1-CDDP system (Fig. 4a), indicating a
synergistic effect between the two drugs. The maximum NMDEI is
present at a concentration of 1 equal to 2.63 μM and a concentra-
tion of CDDP equal to 0.55 μM (Fig. 4b). As can be seen from
Fig. 2b, this combination induces 73.6% mortality, while 1 and
CDDP alone show at the same concentrations as the combination
mortality values of 29.3 and 11.8%, respectively. The same con-
siderations can be done for the systems 2-CDDP and C1-CDDP. In
fact, the maximum NMDEI indicating a synergistic effect is
revealed (Fig. S5a, S5b) at 2 equal to 1.05 μM and CDDP equal to
0.85 μM. This combination induces 81.6% cytotoxicity (Fig. S3),
while 2 and CDDP alone show at the same concentrations as the
combination cytotoxicity values of 19.7% and 18.5%, respectively.
For the C1-CDDP system (Figs. S6a and S6b), a maximum is
revealed at C1 equal to 0.87 μM and CDDP equal to 0.45 μM. This
combination induces 82.8% cytotoxicity (Fig. S4), while C1 and
CDDP alone show at the same concentrations as the combination
cytotoxicity values of 32.9% and 27.5%, respectively.
No negative values of NMDEI are present in any case, indicating
that CDDP and the studied copper(II) complexes do not act
antagonistically in the studied range of concentrations.
4.6. Test of the obtained result
In order to conﬁrm the predicted maxima of NMDEI and to
check the overall predictive ability of the network, new sets of 11
combinations of 1-CDDP, 10 combinations of 2-CDDP and six
combinations of C1-CDDP were prepared (test sets) and the
corresponding cytotoxic activities were measured. These test data
values were corrected for the NAAE and compared with the
calculated values. It was found that all the data predicted by the
network were experimentally conﬁrmed. The test points are
superimposed to the surfaces in Figs. 1, 2, 4 and S3–S6. The quality
of the prediction can also be seen from Fig. 1b, d and f (“o” symbol).
4.7. Mass spectrometry
Since the highest values of NMDEI occurs for almost integer
ratios of copper complexes and CDDP concentrations (5:1, 1:1 and
1:2 Cu(II)/CDDP for 1, 2 and C1, respectively), we veriﬁed the
possible formation of mixed complexes between either 1, 2 or C1
with CDDP by mass spectrometry. Both the LDI and MALDI mass
spectra of the mixtures of Cu(II) complexes and CDDP at 1:5 and
5:1 molar ratios were recorded. No mixed copper-platinum com-
plexes were detected (mass spectra are not shown).
4.8. Comparison with IB and CI methods
4.8.1. Brief description of the methods
The IB method [5] consists of the construction of a graph in
which equally effective doses of two drugs are reported for a single
effect level (isoboles). Once a speciﬁc level is chosen, such as 50%
of the maximum, the doses of the two drugs A and B that give the
same degree of effect are plotted as axial points in a Cartesian plot.
The straight line connecting A and B deﬁnes the combinations that
produce a pure additive effect. The experimental points which fall
below or above that line represent drug combinations that have
synergistic or antagonistic effect, respectively.
The CI method [3,4,6,7] tries to measure the extent of drug
interactions. It considers the existence of a relationship between
the fraction affected (fa) and unaffected (1−fa) by a drug and the
ratio (D/Dm)m, according to Eq. (10), where D is the dose of the
drug and Dm is the median effect dose, i.e. the concentration at
which the drug inhibits the system by 50% (the fraction affected (f)
coincides with the cytotoxic activity divided by 100).
f a
ð1−f aÞ
¼ D
Dm
 m
ð10Þ
The values ofm and Dm are determined by applying a logarithm
to Eq. (10), which gives log (fa/(1−fa))¼m log (D)−m log (Dm) and
plotting the function y¼ log (fa/(1−fa)) vs. x¼ log (D). By linear
ﬁtting, the variables m and Dm can be obtained as the slope and
intercept, respectively.
Once m and Dm are deﬁned, as the second step of the method,
the value of Dx for each drug (Eq. (11)) and ﬁnally the CI (Eq. (12))
have to be calculated (the numbers 1 and 2 indicate the two
Fig. 4. NMDEI surface with experimental data (■ training set, ☆ validation set and ○
test set) (a) and contour plot of NMDEI iso-values (b) for the system 1-CDDP.
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drugs).
Dx ¼Dm
f a
1−f a
 1=m
ð11Þ
CI¼ D
1
D1x
þ D
2
D2x
ð12Þ
A CI lower than, equal to and higher than 1 indicates synergism,
additivity and antagonism, respectively.
4.8.2. Selected examples
Both CI and IB methods require that the concentrations of the
individual drugs and that of their combinations providing the
same cytotoxic effect have to be compared. Let us consider the
solutions reported in Table 1. In the solutions a and b, CDDP and 1
have a concentration of 1.0 and 3.0 μM, respectively; at these
concentrations, they both show a cytotoxicity value of 50%.
Following the IB and CI methods, these two solutions should be
compared with all the combinations which show the same
cytotoxic activity, for example solution c. On the basis of the
results of the isobologram (Fig. S7a, triangle symbol and dotted
line) and of CI calculus (CI¼1.28), this combination presents
antagonistic effect. Instead, in our view, the ﬁnal effect of a
combination should be compared with the effects that the
individual drugs provide at the same concentration. In fact,
solution c should be compared with d and e, i.e. where 1 and
CDDP have the same concentration of their combination. The
drugs 1 and CDDP alone present a cytotoxicity value of 9% and
18%, respectively. Comparing these two values with the cytotoxi-
city of their combination (50%), a clear synergistic effect is evident,
as also pointed out by the NMDEI calculated by our approach,
being positive and higher than zero (NMDEI¼25).
To stress the concept, we can consider the solutions f, g and h. If
we compare the cytotoxic activity of 1 at the concentration of
2.63 μM, which is equal to 29%, and that of CDDP at a concentra-
tion of 0.55 μM, which is equal to 12%, it appears evident that the
cytotoxic activity of their combination (74%) is even greater than a
simple algebraic sum of the effects, and, without any kind of
calculation, a synergistic effect is evident. The CI (CI¼1.23) instead
suggests an antagonistic effect. Note that solution f has the
maximum value of NMDEI (NMDEI¼36, Fig. 4).
The same considerations may be presented for the 2-CDDP
(solutions i−n) and C1-CDDP systems (solutions o-u). In particular,
the solutions l and s that give rise to the maximum value of NMDEI
for the 2-CDDP and C1-CDDP systems, respectively, present a CI
indicating an additive effect (CI¼0.98) or a weak synergistic effect
(CI¼0.88).
Let us now analyze some other results reported in the literature
for the system CDDP-paclitaxel [6] on 833 K teratocarcinoma cells.
Considering the solutions aa, ab and ac, we ﬁnd that the cytotoxic
activity of paclitaxel at 0.01 μM is 88%, that of CDDP at 1.0 μM is
82%, while their combination has a cytotoxic activity of 97%.
According to the CI, this combination has a synergistic effect
(CI¼0.602), but, applying our method, we ﬁnd that the NMDEI
for the two drugs is equal to −1%; therefore, a slight antagonistic
rather than synergistic effect should be considered. Let us now
analyze the solutions ad, ae and af; the compounds paclitaxel at
0.002 μM and CDDP at 0.2 μM present a cytotoxicity value of 43%
and 30%, respectively, while their combination has a cytotoxicity
value of 70%. According to the CI, this combination has a moderate
synergistic effect (CI¼0.815), lower than that shown by the
solution ac, as it is closer to 1. According to our calculation, the
NMDEI of this combination is 10%, indicating a synergistic effect,
unlike the previous case.
Table 1
Results for selected experimental data analyzed using the method proposed in this work and the combination index (CI).
System Solution Conc. of drug1 (μM) Conc. of CDDP (μM) Experimental cytotoxicity (%) NMDEI (%)a CIC.I.b
CDDP a 1.0 50
1-CDDP b 3.00 – 50 – –
c 1.88 0.60 50 25 1.28
d 1.88 – 9 – –
e – 0.60 18 – –
f 2.63 0.55 74 36 1.23
g 2.63 29 – –
h 0.55 12 – –
2-CDDP i 1.25 50 – –
j 0.75 0.80 50 29 1.50
k 0.75 7 – –
l 1.05 0.85 82 44 0.98
m 1.05 20 – –
n 0.85 19 – –
C1-CDDP o 0.98 – 50 – –
p 0.50 0.45 50 16 1.40
q – 0.45 28 – –
r 0.50 – 8 – –
s 0.87 0.45 83 33 0.88
t 0.87 32 – –
u 0.45 28 – –
PAC-CDDPc aa 0.01 – 88 – –
ab 1.0 82 – –
ac 0.01 1.0 97 −1 0.602
ad 0.002 – 43 – –
ae – 0.2 30 – –
af 0.002 0.2 70 10 0.815
a Calculated by Eq. (5).
b Calculated as proposed by Chou [6] (a number greater, lower or equal to 1, indicates antagonism, synergism and additive effect, respectively).
c PAC is paclitaxel [6].
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4.8.3. Our considerations
In our opinion, comparing the concentrations of individual
drugs and that of their combination providing the same cytotoxic
effect, as the CI and IB methods suggest, might lead to misleading
results. A better comprehension of the studied system arises from
a comparison between the effect of a given combination and the
effect that the individual drugs provide at the same concentration.
The CI method tries to explain the cytotoxic effect of drug
mixtures considering the inhibition of enzymatic activity, a
mechanism that follows an exponential trend. In our opinion, this
is actually a limitation. If the mechanism of drug action is not due
only to the inhibition of enzymatic kinetics, then linearizing a
pattern which is not a priori exponential leads to approximate
results. In fact, the application of the logarithm mathematical
operator to linearize a function is justiﬁed only when the trend of
the function is exponential over its entire interval of existence. The
common choice to consider only the points that lie on a portion of
a straight line, i.e. those that lie around the inﬂection point on the
dose–response curve, is not mathematically rigorous and shows
even more the inability of the method to generalize. The limits of
the method are clearly understandable from Fig. S7b–d, where the
data of 1 and CDDP and paclitaxel alone are reported treated
following Eq. (11). As can be seen, the linear ﬁtting of the trend
does not give acceptable results, in particular for 1 and CDDP.
4.8.4. The choice of the combinations
According to Chou [6,7], the most efﬁcient and economical way
to study the combinations of the drugs in order to save data
points, costs and time is to keep the ratio of the concentrations
constant. In our opinion, this procedure is hazardous because
some drug combinations that may exhibit synergism could be lost.
In fact, synergism (as well as antagonism) may be due to chemical
or bio-chemical reactions (formation of adducts, complexes, redox
reactions, ligand/metal exchange, etc.) that depend on the experi-
mental conditions, for example the molar ratio. Therefore, by
working at a constant molar ratio, the optimal combinations of
the drugs might go unnoticed. On the contrary, our method based
on the combined approach of ED and ANN, allows the evaluation
of all the possible combinations on the entire space deﬁned by the
selected concentration intervals.
4.9. Multiple linear regression
As stated in the introduction, the response surface is usually
modeled using MLR methods. These were applied to model the
cytotoxicity response surface and in this section the results are
given. For MLR treatment, the same data used to train the network
(Section 4.1) were used.
Polynomials with the general expression shown in Eq. (13)
were used.
y¼ α0 þ ∑
n
i ¼ 1
αix
i
1 þ ∑
n
i ¼ 1
βix
i
2 þ ∑
n
i ¼ 1
∑
n
j ¼ 1
∑
nn
k ¼ 1
γkx
i
1x
j
2 ð13Þ
At ﬁrst, the concentrations of the two drugs could be consid-
ered uncorrelated to each other. However, because the possible
synergistic or antagonistic effect may be due to a chemical or
biochemical reaction between the drugs, the concentrations of the
drugs are actually related. In fact, models without the interaction
terms (xi1x
j
2) provided non-acceptable regression parameters (con-
ﬁdence lower than 80%).
A third degree polynomial was used for the system 2-CDDP and
a fourth degree polynomial for the systems 1-CDDP and C1-CDDP
(conﬁdence ≥ 95%). Polynomials with a degree higher than four or
lower than two gave unreliable results (conﬁdence ≤ 60%). The
models obtained for the studied systems are given below (y is the
percentage of mortality, x1 and x2 are the concentrations of the
two drugs and RSS is the residual sum of squares):
 System 1-CDDP:
y¼−0:9x41 þ 2:9x31x2 þ 6:1x21x22−2:4x1x32 þ 31:8x42 þ 5:6x31
−33:4x21x2−22:0x1x
2
2−168:4x
3
2−0:659x
2
1 þ 78:3x1x2 þ 276:5x21
−10:8x1−89:1x2 þ 5:1; RSS¼ 141:
 System 2-CDDP:
y¼ 10:4x31−43:2x21x2−9:4x1x22−16:3x32 þ 0:5x21 þ 83:0x1x2
þ61:7x22 þ 4:7x1−12:6x2 þ 2:9; RSS¼ 189:
 System C1-CDDP:
y¼−16:6x41 þ 20:9x31x2 þ 36:0x21x22 þ 39:0x1x32 þ 28:1x42
þ19:0x31−134:4x21x2−151:6x1x22−129:4x32 þ 58:1x21 þ 164:4x1x2
þ164:9x22−9:5x1 þ 11:3x2 þ 0:9; RSS¼ 45:
The response surface was calculated according to a grid with
dimensions of 4040. The calculated and experimental data for
the training sets are in agreement (Fig. S8 a, c and e; R ranges from
0.9972 to 0.9993). On the contrary, no satisfactory agreement is
achieved for both the validation and test sets (R ranges from
0.8870 to 0.9869). The shapes of the obtained response surfaces
are quite irregular, indicating that overﬁtting had occurred (Fig. S8
b, d and f).
Moreover, the polynomial model does not allow for properly
ﬁtting the experimental dose-response curves (Fig. S9) as done by
the neural network (Fig. 3). This result is instead crucial for the
application of the method proposed in this work, as described in
Section 4.5. Finally, the resulting NMDEI surfaces do not agree with
the experimental values (Fig. S10).
5. Conclusions
A generalized and rigorous mathematical form for the deﬁni-
tion of additive effect for an arbitrary number of drugs has been
proposed. An advanced model-free approach of data exploration
and analysis, based on the ANN and ED was set up to predict and
quantify the synergism of drugs.
From the analysis of the calculated cytotoxicity surface, the
drug combinations with the desired cytotoxicity and the related
lowest dose of the drugs can be found. From the analysis of the
calculated NMDEI surface, the drug combination with the highest
synergistic effect can be chosen. Unlike traditional methods, the
use of ANN allows to evaluate the cytotoxicity of all the possible
combinations on the entire space deﬁned by the chosen concen-
tration intervals.
The copper(II) compounds Cu(1,10-orthophenanthroline)
(H2O)2(ClO4)2, [Cu(1,10-orthophenanthroline)2(H2O)](ClO4)2 or
[Cu(1,10-orthophenanthroline)2(imidazolidine-2-thione)](ClO4)2
act synergistically with CDDP. Against in vitro tested cells, the
optimal compositions of the combinations present an anti-
proliferative effect 3 to 6 times greater than that of CDDP alone.
The combinations with the maximum synergistic effect present
high cytotoxic activity (from 74% to 83%), with required doses
signiﬁcantly lower than those needed for the individual drugs. The
predicted combinations that presented the highest synergistic
effect were actually prepared and experimentally tested. In all
cases, the data predicted by the network were experimentally
conﬁrmed.
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Fig. S1. The architecture of the ANN for the system C1-CDDP. 
 
Fig. S2. Plot of the root mean square error (RMSE) vs. the number of epochs for the system 1-
CDDP (- training set, ••• validation set). The optimal number of epochs is shown by an arrow. 
 
 Fig. S3. Response surface with experimental data (■ training set, ☆ validation set and ○ test set) (a) 
and contour plot of cytotoxicity iso-values (b) for the system 2-CDDP. 
 Fig. S4. Response surface with experimental data (■ training set, ☆  validation set and ○ test set) (a) 
and contour plot of cytotoxicity iso-values (b) for the system C1-CDDP. 
 
 Fig. S5. NMDEI surface with experimental data (■ training set, ☆  validation set and ○ test set) (a) 
and contour plot of NMDEI iso-values (b) for the system 2-CDDP. 
 
 Fig. S6. NMDEI surface with experimental data (■ training set, ☆ validation set and ○ test set) (a) 
and contour plot of NMDEI iso-values (b) for the system C1-CDDP. 
 
 Fig. S7. Calculated isobologram for 1-CDDP (triangle and dotted line), 2-CDDP (circle and solid 
line) and C1-CDDP (square and dashed line) systems, for a cytotoxic activity of 50% (a); results of 
the application of the combination index method to the experimental data (concentration and 
cytotoxicity) of 1 (b), CDDP (c) and paclitaxel
*
 (d); linear fitting parameters are: slope = 4.5149, 
intercept = -2.0159 and r = 0.9837 for 1 (b), slope = 4.2859, intercept = 0.02882 and r = 0.9769 for 
CDDP (c), slope = 1.2478, intercept = 0.1020 and r = 0.9868 for paclitaxel (d); *data from ref. 6. 
 Fig. S8. Experimental (■ training set, ☆ validation set and ○ test set) and calculated mortality 
values and response surfaces obtained by multiple polynomial regression for a, b) 1-CDDP, c, d) 2-
CDDP and e, f) C1-CDDP systems; linear fitting parameters for the equation y = mX are: m = 
0.999(8) with r = 0.9983 for the training set, m = 0.91(4) and r = 0.9869 for the validation set, m = 
0.88(4) and r = 0.9597 for the test set for 1-CDDP; m = 1.00(1) with r = 0.9972 for the training set, 
m = 1.35(6) and r = 0.9722 for the validation set, m = 1.02(7) and r = 0.8870 for the test set for 2-
CDDP; m = 0.999(5) with r = 0.9993 for the training set, m = 0.92(4) and r = 0.9149 for the 
validation set, m = 1.09(5) and r = 0.9020 for the test set for C1-CDDP. 
  
Fig. S9. Calculated (-) with multiple polynomial fitting and experimental (■) dose-response data for 
(a) 1, (b) 2, (c) C1 and (d) CDDP (see section 4.9 for fitting parameters). 
 
 Fig. S10. NMDEI surface with experimental data (■ training set, ☆ validation set and ○ test set) 
calculated with multiple polynomial fitting for the a) 1-CDDP, b) 2-CDDP and c) C1-CDDP 
systems. 
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Chapter 2 
Novel approaches to early diagnosis of prion diseases 
 
Introduction 
 
Protein misfolding 
The biological functionality of cells depends on the correct folding of a network of thousands of proteins. 
The information required to fold a protein into a functional and specific three-dimensional structure is 
contained in its amino-acid sequence. Normally, proteins fold properly into their native conformation; 
however, it’s possible that the protein adopts a wrong conformation, which keeps it from carrying out its 
function. This process, known as “misfolding”, is usually hampered by a series of mechanisms of “rescue” 
that include molecular chaperones, whose main role is to protect the incompletely folded polypeptide 
chain from non-productive interactions, and the ubiquitin-proteasome system, which provides the 
degradation of these aberrant proteins (Fink 1999). 
Misfolded proteins show a common characteristic, a high β-sheets content in their secondary structure. 
This particular conformation makes proteins unstable and, in attempt to seek lower energy levels and 
more stability, prone to aggregate in ordered fibrils called amyloid. Amyloid is toxic; its formation and 
deposition is the common pathological event which leads, over time, to protein misfolding disorders 
(PMDs), a large group of pathologies that affect several organs and tissues of the mammalians. PMDs 
are particularly devastating when amyloid is deposited in the central nervous system causing 
neurodegenerative pathologies such as Alzheimer’s (AD), Huntington’s and Parkinson’s disorders, 
amyotrophic lateral sclerosis (ALS) and prion-related diseases. 
 
Prion diseases 
Also known as Transmissible Spongiform Encephalopathies (TSE), prion disorders are invariably fatal 
neurodegenerative pathologies that include Creutzfeldt-Jakob Disease (CJD), Gerstman-Straussler-
Scheinker syndrome (GSS) and fatal familial insomnia in humans, bovine spongiform encephalopathy 
(BSE) in cattle, Scrapie in sheep and goats, chronic wasting disease (CWD) in cervids (Prusiner 2013). In 
human beings, sporadic (~85% of cases), genetic (~15%) or acquired through dietary or medical 
exposure to infected tissues (<5%) forms have been described 
(http://www.cdc.gov/ncidod/dvrd/cjd/index.htm), while in animals only infectious forms have been 
identified (Novakofski et al. 2005). The onset of clinical illness is preceded by a long incubation period 
lasting from months to decades. These diseases are usually neuropathologically characterized by 
spongiform change (microcavitation of the brain), neuronal loss, glial activation and accumulation of an 
abnormal amyloidogenic protein. The clinical features of TSEs, which consist of mental changes, ataxia, 
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and loss of fine control of body homeostasis, are due to massive loss of neuron function in the brain and 
are characteristic of many other fatal neurodegenerative diseases (Prusiner 2004).  
 
The prion protein 
It is now known that the central feature of prion diseases is the post-translational conversion of a normal 
host-encoded protein, the cellular prion protein (PrPC), to an abnormal isoform (PrPSc) (Prusiner 1982; 
Legname et al. 2004). PrPC is a glycoprotein made of ~208 aminoacids (35-36 kDa); it is attached to the 
membrane surface by a Glycophosphatidylinositol-anchor (GPI-Anchor) (Riesner 2003). The exact 
mechanism by which the conversion occurs is still unclear, although it is known that it is required 
interaction between PrPC and aberrant PrPSc isoforms. Proteins interaction and conversion mainly 
happens in specific regions of the plasma membrane named cholesterol rich domains or lipid rafts, and 
it seems influenced by variations of the cholesterol content within these regions (Pani et al. 2010). After 
the abnormal conversion, the prion protein biochemical features change; the aberrant isoform becomes 
rich in β-sheet domains (Nguyen et al. 1995), insoluble in mild detergents, the N-terminal region becomes 
partially resistant to digestion with proteinase K, and thus prone to aggregation and deposition in form 
of ordered fibrils (called amyloid), which triggers cytotoxic effects eventually leading to cell death. (Telling 
et al. 1996; Riesner 2003). 
 
Diagnosis of prion diseases, overlook 
All the diagnosis methods to identify infectious disease nowadays in use fall into two main categories, 
direct and indirect. Direct diagnosis aims to find the infectious agent or its components, for example viral 
genome in blood samples; on the contrary, indirect diagnosis seeks for signs of the presence of the 
infectious agent like molecular (antibodies reactive to its components, variation of molecules, metabolites, 
or gene expression) and/or histopathological markers which are associated to the active presence of that 
particular agent in the host. 
With respect to prion diseases, diagnosis becomes more complicated. Unlike other infectious diseases 
caused by viruses, bacteria, parasites etc., it is not possible to diagnose prion disorders using conventional 
methods such as PCR, serology or culture assays. This is because prions, lacking a nucleic acid 
component, are not life forms that can be cultured. They simply represent abnormal isoforms of the 
physiologic protein (PrPC) that the infected organism do not recognize as foreign; therefore no 
immunological response (production of anti-prion antibodies) is observed. 
The discovery of PrPSc in 1982 (Prusiner 1982; 1998) profoundly changed research on TSEs; it provided 
a molecular marker specific for all prion diseases thus opening an entire new path for direct diagnosis. 
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Direct diagnosis tools for TSE take advantage of the proteic nature of the prion and its biochemical 
features. Many antibodies have been developed to react with PrPSc and immuno-based assays are, so far, 
the only tests to confirm TSE cases, approved by national authorities. 
Currently, definite diagnosis for both human and animal TSE is only possible postmortem. It consists in 
the immuno-detection of pathological PrP in the central nervous system (CNS) and, when suitable, 
histopathological analysis of the brain to look for spongiform changes and gliosis (this could be 
considered as an indirect diagnosis). The TSE surveillance in small ruminants is based on rapid tests using 
brainstem material. All samples with positive result in one of the rapid tests must be retested in the 
national reference laboratory using one of the World Organisation for Animal Health (OIE) approved 
confirmatory methods (Matthews et al. 2008). These are histopathology, immunohistochemistry (IHC), 
electron microscopy and Scrapie-associated fibrils (SAF) immunoblot. For practical reasons, only the 
IHC and immunoblot are routinely performed. 
Although the final confirm comes from post mortem analyses, for what concerns lymphotropic TSEs, 
such as vCJD, Scrapie and chronic wasting disease (CWD), it is possible the use of immunohistochemistry 
for PrPSc on lymphoid tissue. It was shown that vCJD can be diagnosed by detection of PrPSc on tonsil 
biopsy (Hill et al. 1997). Similarly, pathological PrP can be detected in lymphoid tissues 42 days following 
oral exposure of deer to CWD prions (Sigurdson et al. 1999). 
Laboratory diagnosis of TSEs is complicated by the uneven distribution of prions in body tissues; 
depending on the disease, highest concentrations can be consistently found in central nervous system, 
but very low (often under immuno-assay detection limit) in easily accessible peripheral tissues and body 
fluids. Of note, studies conducted by Dr. Zanusso and colleagues that highlighted the presence of PrPSc 
in the the neuroepithelium of the olfactory mucosa of sCJD patients, suggesting olfactory biopsy as a 
novel diagnostic tool in living patients (Zanusso et al. 2003).   
In the last few years, in attempt to overcome detection limits of “traditional immunoassays”, PrPSc 
capability of propagating itself has been exploited to develop several new ultrasensitive assays. These 
assays include include PMCA (Saà et al. 2006), rPrP-PMCA (rPMCA)(Atarashi et al. 2007), standard 
quaking-induced conversion (S-QuIC) (Atarashi et al. 2008), amyloid seeding assay (ASA) (Colby et al. 
2007), Real-Time QuIC (RT-QuIC) (Atarashi et al. 2011) and enhanced QuIC (eQuIC) (Orrù et al. 2011). 
Recently, RT-QuIC was applied to neuroepithelium samples from sCJD patients (Orrù et al. 2014). The 
new sampling procedure, combined with the specific, fast and efficient in vitro amplification provided 
by RT-QuIC could represent a mile stone on the difficult pathway of antemortem diagnosis of human 
prion diseases.   
In the past decade, improvements in mass spectroscopy (MS) techniques and their application to 
proteomics, gave birth to promising tools for protein profiling and biomarker discovery in various types 
of samples such as cell cultures, tissues and biological fluids. These methods allow to identify hundreds 
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of protein in a single run, but due to high abundance of protein in samples, usually a pretreatment is 
required. These techniques have been applied in the research of other protein biomarkers in prion 
diseases as well and led to the identification of several potential candidates in CSF (majority), plasma and 
urine. Currently, sensitivity and specificity of these new potential biomarkers need to be need to be 
verified (Ma et al. 2012). 
At the same time, efforts have been made in finding systemic metabolism changes that could serve as 
early biomarkers of the disease. Of note, studies conducted by my supervisor and collaborators showing 
abnormal levels of cholesteryl ester (up to 3-fold higher) in lymphocytes and skin fibroblasts isolated 
from healthy (carrying a Scrapie-susceptible genotype) and Scrapie-affected sheep, compared to sheep 
with a resistant genotype (Pani et al. 2007a and b). 
 
Chapter 2, part 1 
Brain lipid profile variations as early biomarker for in vitam diagnosis of Scrapie 
 
Sheep Scrapie 
Scrapie is the prototype of TSEs and also the prion disease with the longest history of publication, the 
first authentic report on Scrapie was written in Germany and dates back to 1750 (Leopoldt 1750). It 
affects sheep and goats and is endemic in almost all member states of the European Union as well as in 
Norway, Iceland and Switzerland.  
Brazil, Canada, Israel, Japan, Palestinian Autonomous Territories, Russia, Tajikistan and the USA 
reported Scrapie cases (atypical and/or classical) in the last 6 years. (World Animal Health Data Base 
(WAHID); http://web.oie.int/wahis/public.php?page=disease_timelines). According to the “World 
Livestock Disease Atlas 2011” (Anonymous 2011), Scrapie ranks third worldwide as cause for sheep and 
goat losses. 
Several epidemiological studies showed that the successful transmission of classical Scrapie requires sheep 
with susceptible genotype. Other than susceptibility to the disease, Ovine PrP polymorphisms influence 
and also modulate the progression including the incubation period and clinical signs. The vast majority 
of polymorphisms are due to single nucleotide polymorphisms (SNP) in the DNA, which often cause 
single amino acid changes. Of particular interest are polymorphisms at codons 136, 154 and 171 which 
are clearly linked to Scrapie susceptibility in sheep. The polymorphisms mentioned above can generate 
five different alleles (ARQ, VRQ, AHQ, ARR and ARH) which are the only alleles with significant 
distribution worldwide. The combination of these alleles leads to 15 different genotypes, (Goldmann 
2008). The highest risk to develop Scrapie occurs in VRQ/VRQ animals while the highest genetic 
resistance is associated to ARR/ARR sheep (Hunter 1997). Mode of transmissions of Scrapie were 
broadly discussed in the past decades (Schneider et al. 2008) but even up to now the exact transmission 
routes are not entirely clear. It is known that Scrapie can transmit laterally between sheep, under natural 
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conditions, via direct contact or through contamination of the environment. Oral route is the most 
efficient (Jeffrey et al. 2007; Van Keulen et al. 2008) and the main source of infection is the infectious 
placenta. Infectivity and PrPSc have been detected in the foetal parts, depending on the genotype of the 
offspring (Pattison et al. 1972; Onodera et al. 1993; Race et al. 1998; Andreoletti et al. 2002; Lacroux et 
al. 2007). The placenta and the amniotic fluid are shed into the environment during lambing and their 
ingestion by other sheep (and goats) is still assumed to be the most important infection mode within the 
flock (Pattison et al. 1972; Hoinville 1996). Moreover, it has been shown that Scrapie agent can remain 
infectious even after years in the environment (Brown and Gajdusek 1991; Seidel et al. 2007). Additional 
results indicate that released PrPSc may be sequestered near the soil surface and bound on soil minerals, 
which may then be ingested during grazing of farm animals (Johnson C.J. et al. 2006). Besides the 
placenta, amniotic fluid (Hoinville 1996), faeces (Terry et al. 2011) and milk (Konold et al. 2008; Lacroux 
et al. 2008; Maddison et al. 2009) have been shown to contain PrPSc and/or infectivity. Recent results 
revealed PrPSc also in the oral cavity of Scrapie infected sheep (Maddison et al. 2010; Gough et al. 2012). 
More artificial routes demonstrated in several experimental infections include transmissions via 
subcutaneous inoculation (Stamp et al. 1959; Kratzel et al. 2007), conjunctival exposure (Haralambiev et 
al. 1973), skin scarification (Taylor et al. 1996) and blood transfusions (Houston et al. 2008). 
 
The incubation time of Scrapie depends on the infection route, age at infection, sheep genotype, the 
involved agent strain and the infectious dose. Sheep with VRQ homozygosity have the shortest 
incubation periods (Detwiler and Baylis 2003; Ersdal et al. 2005; Ryder et al. 2004). Iatrogenic infections 
lead to slightly shorter incubation periods (Caramelli et al. 2001). In classical Scrapie, sheep show clinical 
disease usually between 2 and 5 years of age (average age 3.5 years). Although both sexes appear to be 
equally affected, disease manifestations in rams occur often at slightly younger age (Wineland et al. 1998; 
Lühken et al. 2007; McIntyre et al. 2008). However, also shorter and longer incubation periods ranging 
between 1 and up to 11 years were reported (Parry 1983). Scrapie-diseased animals younger than 18 
months are fairly rare (Dickinson and Stamp 1969) although it is usually not possible to establish the time 
of infection in older Scrapie-diseased sheep (Detwiler and Baylis 2003). Isolation of animals from the 
flock is often the first clinical sign, more specific symptoms at the early stage are central nervous system 
deficits and loss of wool caused by pruritus. Affected animals may appear normal but if stimulated by 
stress (i.e. sudden noise, excessive movement and handling) tremor becomes evident. At later stages, the 
animal may even fall down in a convulsive state (Hörnlimann et al. 2007; Ulvund 2007). Not all symptoms 
are always present but usually more than one is noticeable (Hörnlimann et al. 2007). 
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Membrane lipid environment and protein misfolding 
It appears that cholesterol is not uniformly distributed within membranes, but into regions named 
cholesterol-rich and cholesterol poor domains. Among them, those containing saturated sphingolipids 
are the cholesterol-rich domains, also referred to as lipid rafts (London 2002), which float freely in plasma 
membranes carrying a few passenger proteins. When these proteins are activated by a ligand, the lipid 
rafts coalesce to form larger platforms where many different proteins converge in order to perform 
specific functions, such as signalling, processing or transport (Kurzchalia et al. 1999; Simons and Ehehalt 
al. 2002). Examples of raft proteins are receptors for growth factors, signal transducing proteins (P21), 
chemochine receptors, proteins of the MHC classes, antigen receptors, and various proteins with yet 
obscure functions, including cellular prion protein (PrPC). Lipid-rafts are detergent-insoluble regions 
characterized by the presence of free cholesterol (FC). In normal tissue, with the exception of liver and 
adrenal gland, approximately 90% of the total cellular cholesterol resides in membrane raft domains as 
FC, while only a minor amount (approximately 1-10%) is found as cholesterol esters (CE) in shape of 
lipid droplets, a cytoplasmic storage system (Dessì and Batetta 2004a). Since FC levels are critical to the 
maintenance of proper membrane fluidity, as well as to the function and/or activation of raft-resident 
proteins, cells have developed a highly integrated set of homeostatic mechanisms acting in concert to 
finely control intracellular cholesterol levels. The FC found in cell membranes derives either from de novo 
synthesis in the endoplasmic reticulum, or from lysosomes following receptor-mediated uptake of low-
density lipoproteins (LDLs) (Dessì and Batetta 2004b). Membrane FC, however, is in a dynamic state, 
moving back to the ER in response to changing homeostatic conditions in the cell. In fact, if cholesterol 
in the rafts exceeds threshold levels, its excess is promptly transferred to the ER, where it might elicit 
high-order responses from the control proteins embedded. FC in the ER blocks the function of its 
cellular sensor, the SREBP-cleavage-activating-protein (SCAP), which is needed for the proteolytic 
activation of the sterol-regulatory-element-binding-proteins-2 (SREBP-2), a transcriptional factor that 
promotes the expression of the genes involved in cholesterol synthesis (i.e. hydroxyl-methyl-glutaryl-
coenzime A-reductase (HMGCoA-R)) and uptake (i.e. LDL receptor). Free cholesterol in the ER can be 
either used in the assembly of newly formed membrane rafts, and returned to the plasma membrane 
through vesicular transport, or, if in excess, converted to CE by the Acyl-cholesterol-acyl-transferase 
(ACAT) and stored in the cytoplasm as neutral lipid droplets (Maxfield and Tabas 2005). Viceversa, when 
cell membranes need FC, or when CE droplets exceed a critical threshold value, CE can be reconverted 
to FC by the neutral-cholesterol-ester-hydrolase (nCEH). FC can then be recycled to the membranes by 
cholesterol binding protein, such as caveolin-1 (Cav-1), where it can be used to replenish raft domains, 
or if in excess be delivered to extracellular acceptors, namely high-density lipoproteins (HDL), via the 
ATP-binding-cassette-sub-family A-member 1 (ABCA-1) transporter (Albrecht and Viturro 2007). 
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The amount of cholesterol associated with lipid rafts domains exerts profound effects on the functions 
of the raft-resident proteins. For instance, constant low levels of cholesterol within these domains lead 
to a continuous stimulus of cell growth promotion (Wang et al. 2005), or induce PrPC to undergo 
pathologic processes leading to the generation of its corresponding pathogenic form: the PrPSc (Diomede 
et al. 2002). Other studies highlighted that the amyloid fibrils formation process is enhanced by anionic 
phospholipids (i.e. phosphatidic acid, phosphatidylserine, phosphatidylinositol) followed by neutral lipids 
(i.e. cholesterol, cerebrosides, diacylglycerol), zwitterionic phospholipids (i.e. phosphatidylcholine, 
phosphatidylethanolamine, sphingomyelin) and, at last, by anionic lipids without phosphate group 
(Gorbenko and Kinnunen 2006). The formation of fibrils in vitro system was obtained with artificial 
membranes containing phosphatidylcholine, phosphatidylethanolamine, gangliosides, sphingomyelin and 
cholesterol, typical components of the lipid rafts. Given that the lipid clustering to constitute raft domains 
is influenced by the interaction of lipids themselves with cholesterol, membrane formation/trafficking 
and protein distribution in the cellular membrane would be regulated by the cholesterol content (Simons 
and Ehehalt 2002).      
 
Background and Rationale 
Since lipid environment of the cellular membrane and misfolding process seem to influence each other, 
and the lack of studies specifically addressing lipid changes during natural Scrapie, we deemed useful a 
multidisciplinary study in this direction. The research project, supported by a grant from Regione 
Sardegna (Legge Regionale 7 Agosto 2007, N. 7), involved a collaboration with the Zooprophylactic 
Institute of Sassari (IZS) and a group of chemical-physicist and pathologists of the University of Cagliari. 
The study was performed on 18 sheep brains coming from the same Sardinian farm (15 from sheep 
carrying ARQ/ARQ and 3 AHQ/ARQ genotype). Seven of the brains were healthy, 8 were PrPSc positive 
from sheep with clinical Scrapie and 3 were PrPSc positive from sheep without recognizable clinical 
symptoms (asymptomatic). 
IZS group provided the samples and performed the immunohistochemical and western blot analyses to 
highlight and quantify cerebral PrPSc, as well as the quantification of PrP gene expression and other 
proteins involved in cholesterol homeostasis by Real Time PCR such as ACAT1 and CAV1 (data not 
shown, work in progress). 
The following article, published by Chemistry and Physics of Lipids, will show and discuss results on brain 
lipid profile variations during natural Scrapie. 
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Prion  diseases  are  fatal  neurodegenerative  disorders  affecting  many  mammals,  ovine  scrapie  being  the
archetypal  prion  disease.  Several  independent  studies  in murine  and  cell-based  models  of  scrapie  have
highlighted  the  presence  of a link  between  prion  generation  and  lipid alterations;  yet,  no  data  on  natural
disease  are  available.  In  this  study  we  investigated  levels  of total  lipids  and  cholesterol  as  well  as  proﬁles  of
fatty acids  in  brain  homogenates  from  symptomatic  and asymptomatic  scrapie-infected  sheep  vs.  healthy
sheep,  all  belonging  to the  same  ﬂock.  Lipid  extracts  were  analyzed  by  means  of  gas  chromatography  and
high performance  liquid  chromatography.  Data  of fatty  acids  were  submitted  to multivariate  statistical
analysis  to give  a picture  of the  brain  lipid  proﬁles  of sheep.  Interestingly,  results  revealed  abnormalities
in  the  brain  fatty  acid unsaturation  of  infected/symptomatic  animals.  Signiﬁcant  reduction  of  monoene
18:1  n-9 was  detected  in  brain  lipids  from  infected/symptomatic  sheep,  as compared  to  healthy  and
infected/asymptomatic  animals,  and  this  alteration  occurred  in combination  with a signiﬁcant  increase
in  18:0  level.  The  unsupervised  Principal  Component  Analysis  showed  that  infected/symptomatic  and
healthy  sheep  samples  lie  in two  different  regions  of the  plot,  infected/asymptomatic  lie mostly  next
to  healthy.  The  increase  of cerebral  saturated  fatty acids  provides  a rough  indication  of  presumed  alter-
ations  in  lipid  raft  domains  of  nervous  cells  during  scrapie,  suggesting  that  they  may  exist  in  a notable
viscous  liquid-ordered  state.  Such  physicochemical  alteration  would  have  a profound  impact  on the  raft
thermodynamic  properties,  its spatial  organization,  and signal  transduction,  all  potentially  relevant  for
prion generation.
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Prion diseases or Transmissible Spongiform Encephalopathy
(TSE) diseases are fatal neurodegenerative disorders affect-
ing man  and many mammals (Prusiner, 1998; Aguzzi and
Calella, 2009; Schneider et al., 2008). Human prion disor-
ders are Creutzfeldt–Jakob disease, fatal familial insomnia,
Gerstmann–Sträussler–Scheinker syndrome, and Kuru (Prusiner,
1998; Aguzzi and Calella, 2009), while animal diseases include
scrapie of sheep and goats, transmissible mink encephalopathy
in mink, chronic wasting disease in elk, and bovine spongiform
encephalopathy in cattle and exotic ungulates (Prusiner, 1998;
Schneider et al., 2008; Aguzzi and Calella, 2009).
Prions, commonly considered to be the causative agents of TSEs,
are infectious proteins consisting of abnormally folded, partially
protease resistant isoforms of the normal cellular prion protein
(PrPC), generally denoted as prion protein-scrapie (PrPSc) (Aguzzi
∗ Corresponding author. Tel.: +39 070 6754124; fax: +39 070 6754032.
E-mail address: anrosa@unica.it (A. Rosa).
and Calella, 2009; Smith et al., 2012; Pinheiro, 2006). The key
molecular event is the structural conversion of PrPC into PrPSc,
a self-propagating process in which PrPSc acts as a conforma-
tional template recruiting PrPC for further conversion (Verity and
Mallucci, 2011). The misfolding process takes place in particu-
lar cell membrane domains named rafts (Pinheiro, 2006; Simons
and Ehehalt, 2002; Michel and Bakovic, 2007; Fantini et al., 2002).
Lipid rafts are specialized membrane microdomains characterized
by high content of sphingolipids, cholesterol, and saturated fatty
acids, that serve as organizing centers for different cellular pro-
cesses, including trafﬁcking of membrane and membrane-proteins
(Fabelo et al., 2011; Korade and Kenworthy, 2008). Interestingly,
the misfolding of the prion protein has been reported to affect the
raft structure and to alter the lipid–protein and protein–protein
interactions (Bate et al., 2008).
Studies in scrapie-infected mice and cells revealed the presence
of major molecular and biochemical modiﬁcations in the cellular
cholesterol network (Bach et al., 2009; Bate et al., 2008; Pani et al.,
2007; Vascellari et al., 2011). On the other hand, no major differ-
ences were reported in the content/composition of fatty acids, polar
lipids, neutral lipids, phospholipids, and plasmalogens in the brain
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of scrapie-infected mice and hamsters (Pamplona et al., 2008; Guan
et al., 1996; Dees et al., 1985; Heitzman and Skipworth, 1969).
To date, however, although ovine scrapie is the most studied
prion disease (Schneider et al., 2008; Fitzmaurice et al., 2008), very
few papers have been focused on the lipid alterations occurring
during natural scrapie (Pani et al., 2007).
In an attempt to identify a lipid proﬁle linked to prion ailments,
we analyzed and compared the lipid composition of brains from
uninfected (healthy) and scrapie-infected symptomatic (I/sympt)
and asymptomatic (I/asympt) Sarda breed sheep coming from the
same farm where a number of clinical scrapie cases have been
diagnosed. We  determined and compared levels of total lipids,
total cholesterol, and fatty acids by means of gas chromatography
(GC) and high performance liquid chromatography (HPLC) meth-
ods. Furthermore, GC fatty acid data were studied by means of
multivariate statistical analysis. The unsupervised Principal Com-
ponent Analysis (PCA) was applied to picture the fatty acid proﬁles
of healthy and infected sheep. Malondialdehyde (MDA) levels were
also measured in sheep brain homogenates as biochemical marker
of lipid oxidative modiﬁcation.
2. Materials and methods
2.1. Materials
Cholesterol, triolein, trilinolein, standards of fatty acids and fatty
acid methyl esters, and Desferal (deferoxamine mesylate salt), were
purchased from Sigma–Aldrich (Milan, Italy). All solvents used, of
the highest available purity, were also from Sigma–Aldrich. The
methanolic HCl (3 N) was purchased from Supelco (Bellefonte, PA).
All of the other chemicals used in this study were of analytical grade.
2.2. Sheep selection and scrapie diagnosis
The study was carried out on 1 scrapie-affected Sarda sheep
ﬂocks located in Sardinia (Italy). The ﬂock was randomly selected
in Sardinia among those with a history of high clinical incidence
of clinical cases of scrapie. Presence of the disease scrapie in the
ﬂock was conﬁrmed after the notiﬁcation of clinically suspected
cases throughout the active surveillance for scrapie. In this ﬂock,
inside the framework of appropriate actions for eradicating scrapie,
as is stipulated in EC regulations, all sheep carrying susceptible
ARQ/ARQ genotypes must be sacriﬁced.
Thus, a number of the above susceptible animals, with or with-
out neurological signs, were euthanized. At necroscopy, from each
sheep the brains were collected and then divided into two hemi-
spheres before being immediately frozen at −80 ◦C. One half was
submitted to Western Blotting (WB) examination in order to deﬁne
the scrapie status, as described elsewhere (Ligios et al., 2006). In the
light of the WB results we selected 18 brains, 15 from ARQ/ARQ and
3 from AHQ/ARQ sheep. More in detail 7 of the brains were healthy
(identiﬁed from 1H to 7H), 8 were PrPSc positive from sheep with
clinical scrapie (I/sympt) (from 8IS to 15IS), 3 were PrPSc positive
from sheep without clinical scrapie (I/asympt) (from 16IA to 18IA).
For biochemical examination, the remaining half brain of these
sheep was weighed and homogenized in ice for 2 min  in saline solu-
tion, 1:1 weight:volume, using an Ultra Turrax blender. Aliquots
of homogenates (500 mg  of wet brain/mL of saline solution) were
stored at −80 ◦C until lipid extraction. For further information see
Table 1.
2.3. Lipid extraction from brain homogenates
Total lipids were extracted from brain homogenates using the
method described by Folch et al. (1957) by addition of 12 mL  of
CHCl3/MeOH (2/1, v/v) solution. After addition of 3 mL  H2O and cen-
trifugation at 900 × g for 1 h, the CHCl3 fraction was  separated from
the MeOH/H2O mixture. Total lipids in CHCl3 fraction were quanti-
ﬁed by the method of Chiang et al. (1957). Separation of cholesterol
and fatty acids (FA) was obtained by mild saponiﬁcation (Rosa et al.,
2011) as follows: 1 mL  of the CHCl3 fraction, containing the lipids,
from each brain sample, was  dried down and dissolved in 5 mL of
EtOH and 100 L of Desferal solution (25 mg/mL of H2O), 1 mL of a
water solution of ascorbic acid (25% w/v), and 0.5 mL  of 10 N KOH
were added. The mixtures were left in the dark at room tempera-
ture for 14 h. After the addition of 10 mL  of n-hexane and 7 mL  of
H2O, samples were centrifuged for 1 h at 900 × g. The hexane phase
containing the unsaponiﬁable fraction (cholesterol) was collected
and the solvent was  evaporated. A portion of the dried residue was
dissolved in 1 mL  of MeOH and injected into the high-performance
liquid chromatography (HPLC) system. After the addition of a fur-
ther 10 mL of n-hexane to the mixtures, samples were acidiﬁed
with 37% HCl to pH 3–4 and then centrifuged for 1 h at 900 × g.
The hexane phase (saponiﬁable fraction) with FA was  collected,
and the solvent was evaporated. A portion of the dried residue
was dissolved in 1 mL  of CH3CN with 0.14% CH3COOH (v/v), and
aliquots of the samples were injected into the HPLC system. An
aliquot of dried FA was methylated with 1 mL  of methanolic HCl
(3 N) (Rosa et al., 2011; Christie, 1993) for 30 min  at room tem-
perature. After the addition of 4 mL  of n-hexane and 2 mL  of H2O,
samples were centrifuged for 20 min  at 900 × g. The hexane phase
with FA methyl esters was collected, and the solvent was evapo-
rated. The residue was  dissolved in 100 L of n-hexane, and aliquots
of the samples were injected into the GC system. The recovery of
FA and cholesterol during the saponiﬁcation was  calculated using
an external standard mixture prepared by dissolving 1 mg  of tri-
olein, trilinolein, and cholesterol in 5 mL  of EtOH and processed as
samples. All solvent evaporation was  performed under vacuum.
2.4. HPLC analysis
Analyses of cholesterol and unsaturated FA were carried out
with an Agilent Technologies 1100 liquid chromatograph (Agilent
Technologies, Palo Alto, CA) equipped with a diode array detec-
tor (HPLC-DAD). Cholesterol, detected at 203 nm, was measured
with the use of a Chrompack column (Chrompack, Middelburg,
The Netherlands), Inertsil 5 ODS-3, 150 mm × 3 mm,  and MeOH
as the mobile phase, at a ﬂow rate of 0.4 mL/min (Rosa et al.,
2011). Analyses of unsaturated FA, detected at 200 nm, was car-
ried out with a XDB-C18 Eclipse (150 mm × 4.6 mm,  3.5 m particle
size) (Agilent Technologies) equipped with a Zorbax XDB-C18
Eclipse (12.5 mm × 4.6 mm,  5 m particle size) guard column (Agi-
lent Technologies), with a mobile phase of CH3CN/H2O/CH3COOH
(75/25/0.12, v/v/v), at a ﬂow rate of 2.3 mL/min (Rosa et al., 2011).
The temperature of the column was maintained at 37 ◦C.
The identiﬁcation of cholesterol and FA was made using
standard compounds and conventional UV spectra, generated with
the Agilent Chemstation A.10.02 software. Calibration curves of
all of the compounds were constructed using standards and were
found to be linear, with correlation coefﬁcients >0.995.
2.5. GC analysis of FA methyl esters
FA methyl esters were measured on a gas chromato-
graph Hewlett–Packard HP-6890 (Hewlett–Packard, Palo
Alto, CA) with a ﬂame ionization detector and equipped
with a cyanopropyl methylpolysiloxane HP-23 FAME column
(30 m × 0.32 mm × 0.25 m)  (Hewlett–Packard). Nitrogen was
used as a carrier gas at a ﬂow rate of 2 mL/min. The oven tempera-
ture was set at 175 ◦C; the injector temperature was set at 250 ◦C;
and the detector temperature was set at 300 ◦C. The FA methyl
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Table 1
Summary of cases.
Sample PrPSc Genotype Sex Age (months) Brain weight (g) Group
1 − ARQ/ARQ F 30 60.7 Healthy
2  − ARQ/ARQ F 30 53.2
3  − ARQ/ARQ F 54 50.2
4  − ARQ/ARQ F 54 54.0
5  − ARQ/ARQ F 30 47.7
6  − AHQ/ARQ F 30 54.5
7  − ARQ/ARQ F 30 57.2
8  + ARQ/ARQ F 24 45.1 Infected symptomatic (I/sympt)
9  + ARQ/ARQ F 24 49.0
10  + ARQ/ARQ F 24 45.0
11  + ARQ/ARQ F 36 50.0
12  + ARQ/ARQ F 24 58.2
13  + ARQ/ARQ F 54 63.9
14  + AHQ/ARQ F 18 46.1
15  + AHQ/ARQ F 18 53.0
16  + ARQ/ARQ F 54 57.3 Infected asymptomatic (I/asympt)
17  + ARQ/ARQ F 54 60.6
18  + ARQ/ARQ F 30 53.0
esters were identiﬁed by comparing the retention times to those
of standard compounds. The composition of individual FA was
calculated as a percentage of the total amount of FA (g %), using
the Hewlett–Packard A.05.02 software.
The following FA indices were also calculated: saturated
FA (SFA); unsaturated FA (UFA); monounsaturated FA (MUFA);
polyunsaturated FA from n-3 and n-6 series (PUFA n-3 and PUFA n-
6); average chain length (ACL) = [(%Total14 × 14) + (%Total16 ×
16) + (%Total18 × 18) + (%Total20 × 20) + (%Total22 × 22)]/100;
double bond index (DBI) = [(1 × % monoenoic) + (2 × %
dienoic) + (3 × % trienoic) + (4 × %  tetraenoic) + (5 × %
pentaenoic) + (6 × % hexaenoic)], and peroxidizability index
(PI) = [(0.025 × %  monoenoic) + (1 × %  dienoic) + (2 × %
trienoic) + (4 × % tetraenoic) + (6 × %  pentaenoic) + (8 × %
hexaenoic)] (Pamplona et al., 2008).
2.6. Analyses of free unsaturated FA in the brain
Aliquots (1 mL)  of CHCl3 fractions obtained from brain
homogenates by the Folch et al. procedure, were dried down and
dissolved in CH3CN with 0.14% CH3COOH (v/v). Aliquots of these
solutions were injected into the HPLC system. Quali-quantitative
composition of free unsaturated FA (FFA) was performed as previ-
ously reported in the Section 2.4.
2.7. Measurement of the oxidation product MDA
MDA  levels were measured in brain homogenates in saline
solution (1 mL)  by TBARS test as described by Rosa et al. (2012).
MDA–TBA adduct quantiﬁcation was conducted by HPLC-DAD
analysis using a reverse phase column Varian Inertsil ODS-2
(150 mm × 4.6 mm)  and the mixture of KH2PO4 50 mM pH 7/MeOH
(65%/35% v/v) as mobile phase at a ﬂow rate of 1 mL/min. The adduct
MDA–TBA was  revealed at 532 nm.
2.8. Statistical analysis
Evaluation of statistical signiﬁcance of differences was  per-
formed using Graph Pad INSTAT software (GraphPad software,
San Diego, CA, USA). Comparison between groups was assessed
by one-way analysis of variance (One-way ANOVA) followed by
the Bonferroni Multiple Comparisons Test. The data used to calcu-
late the means and standard deviations for each group/parameter
Fig. 1. Values of total lipids (TL) and total cholesterol (Total Chol) (expressed as
mg/g brain) measured in the healthy (Healthy) and the scrapie-positive groups,
infected/symptomatic (I/sympt) and infected/asymptomatic (I/asympt). *P < 0.05
versus Healthy group;◦◦P < 0.01 versus I-sympt group.
represent the average of at least two separate experiments, involv-
ing triplicate or duplicate analyses for each brain sample.
2.9. Multivariate data analysis
A PCA was  applied to the fatty acid composition as obtained
by GC. The data set consisted of a 18 × 17 matrix, in which rows
represented samples and columns the mean fatty acid content.
The generated ﬁle was imported into SIMCA-P+ program (Version
13.0, Umetrics, Umeå, Sweden), when necessary variables were log
corrected, data were submitted to mean-centering and UV (unit
variance) scaling before PCA.
3. Results
3.1. Lipid components of brain homogenates
Lipid fractions were extracted from brains of healthy (n = 7),
I/sympt (n = 8), and I/asympt (n = 3) sheep. Average values
(expressed as mg/g of wet brain homogenate) of total lipids (TL),
obtained by Chiang procedure, and total cholesterol (Total Chol),
measured by HPLC analysis after mild saponiﬁcation, are shown in
Fig. 1. TL lipid and Total Chol values of 75.7 ± 9.7 and 18.6 ± 1.8 mg/g
of brain, respectively, were measured for healthy animals. The con-
tent of Total Chol in the brains of I/sympt group was  signiﬁcantly
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Fig. 2. GC chromatographic proﬁle (A), composition (expressed as percentage of total fatty acids, % FAME) (B), and total values (%) of saturated (SFA) monounsaturated
(MUFA), and polyunsaturated (PUFA) (C) of fatty acids from brains of the healthy group (Healthy) and the scrapie-positive groups, infected/symptomatic (I/sympt) and
infected/asymptomatic (I/asympt). **P < 0.01, *P < 0.05 versus Healthy group; ◦P < 0.05 versus I-sympt group.
lower than in the other groups. The same trend, although not sta-
tistically signiﬁcant, was observed for TL.
Quali-quantitative information on the individual FA that com-
pose cerebral lipids was obtained by GC (expressed as % of total
FA) and HPLC (expressed as mg/g wet brain homogenate) analyses.
Fig. 2 reports the brain FA proﬁles as measured by GC. In particular,
Fig. 2A shows, as an example, the total FA chromatographic proﬁle
of a healthy animal brain. Fig. 2B and 2C report the measured values
of FA for all samples.
The lipids of healthy sheep brains were characterized by a con-
centration of approximately 27.2% of saturated FA (SFA, mainly 16:0
and 18:0, with percentages of 16.2% and 10.2%, respectively), 36.6%
of monounsaturated (MUFA, mainly oleic acid 18:1 n-9, 18:1 n-7,
and 16:1 n-7; 29.1, 4.0, and 0.6%, respectively), and 27.0% of polyun-
saturated (PUFA, mainly 22:6 n-3 DHA, 20:4 n-6 AA, and 22:4 n-6;
11.3, 7.1, and 4.8%, respectively) (Fig. 2B and C). Individual fatty
acid levels of lipid brains from healthy subjects revealed the pres-
ence of signiﬁcant contents of monoene fatty acids, with 18:1 n-9
representing the most abundant FA in the sheep brain, as reported
by other studies (Rajion et al., 1985), followed by 16:0, DHA, and
18:0. PUFA of the n-6 and n-3 series accounted for 13.9% and 12.1%
of total brain FA, respectively.
Very little differences between I/asympt and healthy animals
could be detected in brain total FA proﬁle, nevertheless differences
were detected between these two groups and I/sympt group (Fig. 2B
and C). Total value of MUFA in I/sympt animals was  signiﬁcantly
lower than in healthy and I/sympt animals, coupled to an evident,
but not statistically signiﬁcant, increase in total SFA level. Specif-
ically, signiﬁcant lower level of 18:1 n-9 and higher amount of
the SFA 18:0 (also 16:0 and 20:0, though to a minor extent) were
measured in I/sympt group with respect to healthy animals. Fig. 3
shows the distribution of the values (as % of total FA) of SFA, MUFA
(Fig. 3A), 18:0, and 18:1 n-9 (Fig. 3B), measured for each individual
brain sample of the healthy (1H–7H samples), I/sympt (8IS–15IS),
and I/asympt (16IA–18IA) animal groups. Each value is the mean
and standard deviation of at least two  independent experiments
involving duplicate/triplicate analyses for each brain sample.
The fatty acid indices: PUFA n-3, PUFA n-6, PI, DBI, ACL, were
also determined and results are summarized in Fig. 4. No signiﬁcant
differences were observed in these global indices, among groups.
Furthermore, the content of the main unsaturated FA in brains of
healthy animal group was detected by HPLC as follows: 6.40 mg/g of
wet brain homogenate of 18:1 n-9, 2.41, 1.32, and 1.07 mg/g of DHA,
AA, and 22:4 n-6, respectively, as reported in Fig. 5A. A lower (but
not signiﬁcant) level of 18:1 was measured by HPLC quantiﬁcation
in brains of I/sympt group with respect to healthy and I/asympt ani-
mals, however no changes were seen for other PUFA. The oxidative
product MDA  was  also measured by HPLC in brain homogenates,
and results reported in Fig. 5B. A slight, but not statistically signif-
icant, increase of this compound was observed in I/sympt animals
with respect to healthy and I/asympt groups.
Quali-quantitative information on brain levels of unsaturated
free FA (FFA) were obtained by direct HPLC analysis of the chlo-
roform fraction obtained from Folch extraction. Fig. 6 shows the
values of the main brain unsaturated FFA (18:1, AA, 22:4 n-6, and
DHA), expressed as g/mg lipid/g of wet  brain (Fig. 6A) and as
% of the sum of the four individual FFA (Fig. 6B), measured in
brains of the healthy and the prion-positive groups, I/sympt and
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Fig. 3. Values (expressed as percentage of total fatty acids) of saturated (SFA), monounsaturated (MUFA) fatty acids (A), 18:0, and 18:1 n-9 (B), from brains of the healthy
samples (1H–7H) and the scrapie-positive samples, infected/symptomatic (I/sympt, 8IS–15IS) and infected/asymptomatic (I/asympt, 16IA–18IA).
Fig. 4. Values (expressed of % Healthy) of the fatty acid indices: peroxidability index (PI), double bond index (DBI), average chain length (ACL), and n-6 and n-3 polyunsaturated
fatty  acids (PUFA n-6 and PUFA n-3), measured in the healthy group (Healthy) and the scrapie-positive groups, infected/symptomatic (I/sympt) and infected/asymptomatic
(I/asympt).
I/asympt. The proﬁle of unsaturated FFA in the brains of healthy
group (Fig. 6A) was quite different from that of total unsaturated
FA (Fig. 5A), and it was characterized by higher levels of AA and 18:1
n-9 (0.60 and 0.53 g/mg lipids/g brain, respectively) followed by
minor level of DHA and 22:4 n-6. No signiﬁcant differences in the
absolute amounts of FFA were observed among different groups.
Interestingly, the analysis of the % values (Fig. 6B) revealed signiﬁ-
cant higher % of DHA, coupled to a lower proportion of AA, in brains
of I/sympt group with respect to healthy and I/asympt groups.
3.2. Multivariate data analysis (MVA)
The FA content of lipid extracts of brain samples measured by
means of GC, and reported as area %, was  submitted to PCA. PCA
is an unsupervised analysis and, as such, it requires no informa-
tion about the class membership of samples. The ﬁrst two principal
components explained the 52% of total variance. Results are shown
in the loading bi-plot (Fig. 7A). The loading bi-plot reports the com-
plementary information usually shown in terms of score (samples)
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Fig. 5. Values of the main unsaturated fatty acids (18:1, 20:4 n-6, 22:4 n-6,
and 22:6 n-3) (expressed as mg/g of wet brain) (A) and malondialdeyde (MDA)
(expressed as % control) (B) measured by HPLC, in the brains of the healthy group
(Healthy) and the scrapie-positive groups, infected/symptomatic (I/sympt) and
infected/asymptomatic (I/asympt).
plot and loading (variable) plot. Hence, this plot allows to visual-
ize the fatty acid proﬁle that characterizes samples and/or sample
clusters; results can be interpreted following the rule: samples sit-
uated near the variables are high in these variables and are low
in variables situated opposite in the plot area, variables that are
found in the same area of the plot are positively correlated among
themselves and negatively correlated with variables lying in the
opposite side of the plot (Eriksson et al., 2006). The bi-plot shows
Fig. 6. Values, expressed as g/mg lipid/g of wet  brain (A) and % (B), of the main
free unsaturated fatty acids (18:1, 20:4 n-6, 22:4 n-6, and 22:6 n-3) measured, by
HPLC, in the brains of the healthy group (Healthy) and the scrapie-positive groups,
infected/symptomatic (I/sympt) and infected/asymptomatic (I/asympt). **P < 0.01
versus Healthy group.
that I/sympt and healthy sheep samples lie in two different regions
of the plot, I/asympt lie mostly next to healthy. SFA characterize the
positive part of PC1 together with 18:2 n-6; in the opposite side it
is possible to see the highly unsaturated FA (both n-3 and n-6) and
the 18:1 isomers next to 20:3 n-9 FA.
These results indicate that the overall FA proﬁles differ among
healthy and I/asympt vs. I/sympt sheep brains. Given that such FA
Fig. 7. Bi-plot of a Principal Component Analysis (PCA) of GC data. Variables: 5 points stars = * fatty acids. Samples: (A) red box healthy samples (Healthy), green cir-
cle  = infected/symptomatic (I/sympt) and blue triangle = infected/asymptomatic (I/asympt); (B) samples colored by age of sheep as reported in the plot legend. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web  version of this article.)
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distribution could be, even partially, driven by the different ages
of animals, samples in the bi-plot have been colored depending on
sheep age as reported in Table 1; results (Fig. 7B), however, indicate
that this was not the case.
4. Discussion
Ovine scrapie represents the archetypal prion disorder, with a
long history of investigation (Schneider et al., 2008; Jeffrey et al.,
2009; Fast and Groschup, 2013). To date, however, studies mainly
addressed genetic and pathological features (Fast and Groschup,
2013; Ligios et al., 2002; Hunter, 1997,2003), cytotoxicity and neu-
ropathology of PrPSc isoforms (Jeffrey et al., 2009; Filali et al., 2012),
and transmission routes (Ligios et al., 2011; Fast and Groschup,
2013; Hunter, 2003), while only few studies have investigated lipid
modiﬁcations during natural infection and, also in that case, it
focused only on the cholesterol alterations (Pani et al., 2007).
In the present study, we analyzed and compared the brain lev-
els of TL, Total Chol, and FA of healthy, I/sympt, and I/asympt Sarda
breed sheep coming from a farm affected by natural scrapie. Our
data failed to reveal severe alterations in lipid composition among
different groups. Nevertheless, some interesting differences were
in general observed in I/sympt animals with respect to healthy and
I/asympt; these latter two showing similar lipid characteristics.
Brains from I/sympt group showed the lowest levels (expressed
as mg/g weight brain) of TL and Total Chol, probably due to
the severe brain degeneration (spongiosis, neuronal vacuolation,
gliosis) existing in the clinical stage of scrapie (Kimberlin, 1969;
Fast and Groschup, 2013). No signiﬁcant differences were previ-
ously observed (Pani et al., 2007) in brain total cholesterol level
between unaffected and affected ARQ/ARQ scrapie-susceptible
animals, while a noteworthy difference was evinced in brain
samples from the scrapie-resistant ARR/ARR sheep as com-
pared to the unaffected or affected scrapie-susceptible ARQ/ARQ
sheep.
Interestingly, our data revealed abnormalities in the brain FA
unsaturation of I/sympt animals. Generally, the degree of FA unsa-
turation in membrane phospholipids determines the biophysical
properties of the membrane, which in turn inﬂuences many crucial
membrane-associated functions. The alteration of the degree of FA
unsaturation in cell membrane has also been implicated in a vari-
ety of pathological states, including neurological diseases (Ariyama
et al., 2010). We  found that brain lipids from ill subjects were
enriched in SFA, as compared to healthy and I/asympt animals. Sig-
niﬁcant reduction of monoene 18:1 n-9 was detected in brain lipids
from I/sympt samples, and this alteration occurred in combination
with a signiﬁcant increase in 18:0 level. The ratio 18:1 n-9/18:0
resulted 2.97 ± 0.31, 2.40 ± 0.30, 2.69 ± 0.25 in brain lipids from
healthy, I/sympt, I/asympt animals, respectively. Nevertheless, no
signiﬁcant differences were observed in fatty acid indices: PUFA
n-3, PUFA n-6, PI, DBI, ACL, among groups. Furthermore, the mul-
tivariate statistical analysis of FA composition conﬁrmed that the
overall FA proﬁles differ among healthy and I/asympt vs. I/sympt
sheep brains, and FA distribution was not affected at all by age.
Previous reports showed no differences in brain FA composition
in normal and scrapie-affected mice (Guan et al., 1996; Heitzman
and Skipworth, 1969), or lower intensity changes in FA proﬁle (a
signiﬁcant decrease in MUFA level) in Syrian hamsters affected by
prion disease with respect to control brain (Pamplona et al., 2008).
On the other hand, signiﬁcant alterations in the brain lipid compo-
sition was detected in the brain of patients with Creutzfeldt–Jakob
disease (such as decrease of PUFA and increase of 16:0) (Pamplona
et al., 2008).
Several lines of evidence implicate the role of lipid rafts in the
conformational transition of prion proteins (Pinheiro, 2006; Simons
and Ehehalt, 2002; Michel and Bakovic, 2007; Fantini et al., 2002)
and the formation of PrPSc has been proposed to alter conven-
tional lipid raft structure and the PrPC-protein interactions that
occur within lipid rafts (Bate et al., 2008). Lipid rafts comprise a
highly dynamic clustering of proteins and lipids that play a cen-
tral role in signal transduction and intercellular communication
(Fabelo et al., 2011). Lipid raft domains are mainly character-
ized by a high content of sphingolipids containing saturated acyl
chains and cholesterol; furthermore, phosphatidylcholine, mainly
with saturated acyl chains, is present, as well as small amounts
of phosphatidylethanolamine and phosphatidylserine (Michel and
Bakovic, 2007). The specialized lipid composition of lipid rafts may
inﬂuence protein function directly by modulating the properties of
the membrane bilayer (Korade and Kenworthy, 2008).
Interestingly, our data showed that there was  a trend for
increase in the SFA content of brain lipids in I/sympt animals.
The relationship 18:1 n-9/18:0 observed is physicochemically rel-
evant since the ratio between these two  fatty acids represents an
evolutionary conserved mechanism to preserve the homeoviscous
state of cell membranes in response to different forms of phys-
ical and/or chemical stress (Fabelo et al., 2011). The increase of
brain SFA furnishes a rough indication of presumed lipid alter-
ations in lipid membranes/rafts, indicating that in scrapie-affected
sheep lipid rafts may  exist in a notable viscous liquid-ordered state.
Such physicochemical alteration would have a profound impact in
the lipid raft thermodynamic properties, spatial organization, and
signal transduction.
In general, the fatty acid composition of membrane phospho-
lipids is likely to be affected by the exogenous FA from the diet
or by altered activities of lipid-metabolizing enzymes such as fatty
acid desaturases (Ariyama et al., 2010). Taking into consideration
that all the sheep came from the same farm, it can be supposed
that the signiﬁcant increase in saturated 18:0 and the reduction
in 18:1 n-9 in brains of I/sympt animals may be indicative of a
down-regulation of 9-desaturase, the enzyme responsible for the
synthesis of n-9 monounsaturated fatty acids from their saturated
precursors (Fabelo et al., 2011). This would result in a concomi-
tant loss of the ability to adjust lipid raft physical order (Fabelo
et al., 2011). Overload of saturated long chain fatty acids within cells
is also known to cause lipotoxicity, which contributes to various
pathological conditions (Ariyama et al., 2010).
Oxidative stress is considered to be one of the key factors in
the pathogenesis of prion disease (Yun et al., 2006; Pamplona et al.,
2008; Filali et al., 2012). For example, the brain undergoes oxidative
stress in the early stages of prion invasion into the brain and may
predispose the brain to neurodegenerative mechanisms (Filali et al.,
2012). Our data showed an increase, but not statistically signiﬁcant,
of the oxidative product MDA  in I/sympt animals with respect to
healthy and I/asympt groups, without signiﬁcant changes in PUFA
levels and peroxidability indexes.
Several observations strongly implicate phospholipases A2
(PLA2) in the pathogenesis of prion diseases (Farooqui et al., 2006;
Bate et al., 2008). Our data did not reveal signiﬁcant differences in
the absolute amounts of brain free unsaturated FA (18:1, AA, 22:4
n-6, and DHA) among different animal groups. Nevertheless, differ-
ent unsaturated FFA ratios were observed in brains of I/sympt group
with respect to healthy and I/asympt groups. The phospholipase
A2 family includes secretory phospholipase A2(sPLA2), cytosolic
phospholipase A2 (cPLA2), plasmalogen-selective phospholipase
A2(PlsEtn-PLA2), and calcium-independent phospholipase A2
(iPLA2); various isoforms of PLA2 probably act on different cel-
lular pools of phospholipids located in different types of neural
cells (Farooqui et al., 2006). Brain sPLA2 shows no selectivity for
particular fatty acyl chains in the phospholipids; cPLA2 prefers AA
over other fatty acids, while PlsEtn-PLA2 hydrolyzes AA and DHA
from the sn-2 position of plasmalogens (Farooqui et al., 2006). The
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activation of cPLA2 has been previously demonstrated in differ-
ent prion models (Bate et al., 2008), and increased cPLA2 and
PlsEtn-PLA2 activities have been measured in brain of patients
with neurodegenerative disease (Farooqui et al., 2006). The differ-
ent unsaturated FFA ratios observed among animal groups maybe
due to an implication of different phospholipases that speciﬁcally
cleave the acyl ester bond at the sn-2 position of membrane phos-
pholipids to produce a mixture of free fatty acids (Farooqui et al.,
2006).
In conclusion, data herein reported, although suggestive of a
modiﬁed cerebral lipid environment during prion infection, do
not allow to establish the relevance of lipid modiﬁcations in the
progression of scrapie, nor the presence of a mechanistic link
between speciﬁc lipid changes and generation of the prion pro-
tein. To speciﬁcally address these issues, time course experiments
in lambs experimentally infected with scrapie are in progress.
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Chapter 2, part 2 
Rapid antemortem detection of CWD prions in deer saliva by RT-QuIC 
 
Chronic wasting disease 
Chronic wasting disease (CWD) is a prion disease that affects cervids such as mule deer (Odocoileus 
hemionus), white-tailed deer (Odocoileus virginianus), Rocky Mountain elk (Cervus elaphus nelsoni), and Shira’s 
moose (Alces alces shirasi) (Williams and Young 1980; Williams and Young 1982; Baeten et al. 2007). It 
was officially identified as a new Transmissible Spongiform Encephalopathy (TSE) in 1978 by 
pathologists Williams and Young (Williams and Young 1980). Since then, it is only known to occur in 
North America, Canada and in South Korea (Dubè et al. 2006; Kahn et al. 2004; Kim et al. 2005; Williams 
et al. 2005).  
Only few amino acid residues differ in the prion protein gene among cervids (Aguzzi and Polymenidou. 
2004; Jewell et al. 2005; O’Rourke et al. 1999). As for other prion diseases, species-specific 
polymorphisms affect susceptibility to CWD infection. In naturally infected mule deer, serine 
homozygosity at codon 225 seems to increase risk for CWD infection while in Elk risk along with a faster 
progression of the disease is associated with polymorphism at codon 132 (M/L) (Hamir et al. 2006; 
O’Rourke et al. 2007). White-tailed deer also have a polymorphism at Prnp codon 96 (S/G) (Johnson et 
al. 2006). In naturally infected white-tailed deer, deer that expressed 96SS PrP had a lower risk for CWD 
infection, but were not resistant (Johnson et al. 2006; O’Rourke et al. 2004). Other studies suggest that 
the 96S allele delays CWD disease progression (Wolfe et al. 2007). Perhaps these two allelic genotypes 
select for different CWD strains. 
CWD is characterized by very efficient horizontal transmission among cervids (Miller and Williams 2003) 
but not towards other species human included (Mawhinney et al. 2006). Mechanism of spreading range 
from direct contact among animals to environmental exposure; blood, urine, saliva and feces from 
infected animals have been shown to contain infectivity (Haley et al. 2009; Mathiason et al. 2006; 
Tamguney et al. 2009) and prion infectivity has been recovered from soil more than 2 years after 
exposure; therefore, other than cervids, also tainted soil represent a reservoir for CWD prions (Seidel et 
al. 2007). 
Clinical signs of CWD in deer and elk are unspecific and subtle in early disease and commonly include 
weight loss and behavioral changes such as isolation from the herd and depression. Other signs may 
include hypersalivation, polydipsia/polyuria, ataxia, and occasionally increased regurgitation and/or 
esophageal distension. 
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Background and Rationale 
The social behavior of some susceptible cervids drives them to congregate in herds that can seasonally 
migrate through wide areas. This behavior combined to the ease in horizontal transmission makes 
keeping track of the new cases fundamental. At the moment, the detection tools used to detect CWD are 
laborious, impractical, especially for a wildlife screening approach, and time-consuming. The 
examinations usually include immunohistochemistry, western blotting and PMCA of tonsil and rectal 
(RAMALT) biopsies or retropharyngeal lymph nodes (Sigurdson 2008).  
 
From the end of May 2012 until November 2013 I had the chance to spend part of my Ph.D. program 
at the Rocky Mountain Laboratories, a NIH facility located in Hamilton (Montana, USA). I worked under 
Dr. Byron Caughey supervision. 
In 2008, Dr. Caughey’s group developed a new in vitro amplification assay for prions called “QuIC” 
(Quaking-Induced Conversion) (Atarashi et al. 2008); I worked with the evolution of the QuIC assay, 
called RT-QuIC (Atarashi et al. 2011). 
RT-QuIC assay is a very promising and powerful tool in the detection of abnormal form of prion protein. 
So far, it has been successfully applied to several prion diseases like sporadic Creutzfeldt-Jakob disease 
(sCJD) (Atarashi et al. 2011), variant CJD (vCJD) (Orrù et al. 2011), genetic human prion diseases (Sano 
et al. 2013) and CWD (Henderson et al. 2013).  
In the RT-QuIC assay, soluble recombinant PrP (rPrP-sen) expressed in E. coli is used as a substrate to 
amplify the minute amounts of abnormal PrP. We know that when the aberrant form of the prion protein 
gets in contact with the normal one it can induce the misfolding. The conversion is normally very slow, 
in the RT-QuIC it is enhanced by vigorous intermittent shaking which induces the misfolding of rPrP-
sen and therefore the aggregations and formation of fibrils. The formation of the amyloid fibrils is then 
monitored/detected using thioflavin T (ThT) that specifically binds amyloid becoming fluorescent. It is 
called Real Time because it is possible to check the reaction step by step, reading the fluorescence at 
specific time points. (Fig. 1). 
RT-QuIC assay is opening the road for new peripheral samples otherwise difficult or unsuitable to test 
with other methods. This assay appears to be more convenient than others nowadays in use from several 
points of view; high sensitivity and specificity, user-friendly (extremely easy to set up and repeat) and 
high-throughput. 
During the last months I worked on the setting up of the RT-QuIC assay to detect salivary prions in 
CWD positive white tail deer (WTD) which could be a sensitive, specific, and rapid ante-mortem test for 
accurate diagnosis of CWD.  
This work was recently published by Plos One (see following article). 
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Figure 1. RT-QuIC assay main features. 
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Introduction
Chronic Wasting Disease (CWD) is a transmissible
spongiform encephalopathy (TSE), or prion disease, that
affects free-ranging and captive cervids [1,2]. CWD appears to
be the most transmissible of the prion diseases, and is now
recognized in twenty-two U.S. states, as well as two Canadian
provinces and the Republic of Korea (http://
www.nwhc.usgs.gov/). Experimental studies have
demonstrated that CWD prions can also infect several outbred
non-cervid species [3–9]. Thus the emerging prevalence of
CWD poses a challenge to wildlife management agencies,
free-ranging and captive cervid populations, the hunting and
food producing animal economies, and may pose a zoonotic
risk. Ideally, monitoring for CWD prions would be carried out on
minimally invasive biologic samples (such as saliva, blood,
urine or feces) harvested from live animals in the field.
However, rapid, sensitive and specific ante-mortem detection
of CWD and other prion diseases remains a challenge due to
the low concentrations of prions and the presence of inhibitors
in body fluids and excreta [10–13].
The salient feature of prion disease is the conversion of the
normal cellular prion protein (PrPC) to a misfolded, pathogenic
and transmissible form, often designated as PrPRes, PrPSc, or
PrPD [14–16]. The normal prion protein (PrPC), expressed at
highest level in the central nervous system [17,18], is
composed of ~250 amino acids with a predominantly unfolded
N-terminal region and a C-terminal domain that is folded,
globular, and contains three α-helices and two short β-sheet
stretches [19,20]. The formation of the misfolded pathogenic
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prion is thought to occur through PrPRes-templated conversion
of the predominantly α-helical C-terminal region of PrPC to a
high β-sheet oligomeric conformer, thereby conferring partial
protease resistance [21–23]. The degree of protease-
resistance of PrPRes varies markedly from oligomers to large
amyloid fibrils, with the smaller particles tending to be more
infectious per unit protein [24]. Bioassay studies in deer have
demonstrated infectious prions in the saliva, urine, blood and
feces of infected deer [25–27]. However, due to the low
concentration of PrPRes detectable in biological fluids or excreta
and the potential that the infectious prions may be relatively
protease-sensitive, the timing, source and biochemical nature
of peripheralized/excreted prions remain poorly understood.
Thus, detection of the low levels of prion protein in body fluids
will likely require in vitro amplification such as that provided by
serial protein misfolding cyclic amplification (PMCA) [28–31].
PMCA has been very successfully applied to tissue samples,
however, detection of prions in some body fluids has been
hampered by the presence of inhibitors in biological fluids and
excreta. Nevertheless, the detection of scrapie prions by
multiple rounds of PMCA performed on oral swab eluates from
scrapie-infected sheep [32] and blood of hamsters [29] has
demonstrated the potential for detection of very low levels of
prions in body fluids through in vitro amplification methods.
Real-time quaking conversion (RT-QuIC) [33,34] relies on
the seeded conversion of recombinant PrPC to a thioflavin T
(ThT)-binding amyloid-like PrP form and offers the potential for
sensitive ante-mortem detection of prions in a single round
assay [35,36]. Here we report adaptations of RT-QuIC to detect
CWD prions in the saliva of CWD-exposed pre-symptomatic
and symptomatic deer. These data support the promise of RT-
QuIC methodology both for sensitive prion detection in live
animals and as a means to help elucidate the mechanisms of
prion conversion, peripheralization and transmission.
Materials and Methods
Expression and purification of rPrP
RT-QuIC assays were performed with recombinant Syrian
hamster PrP (SHrPrP) encoding residues 90-231 in Pet 41 and
expressed and purified as previously described [34]. In brief, 1
liter cultures of LB containing Auto Induction™ supplements
(EMD Biosciences) were inoculated with SHrPrP expressing
Rosetta strain E. coli, grown overnight, and harvested when
OD (600 nm) of ~3 was reached. Cells were lysed with Bug
Buster™ reagent with supplemented Lysonase™ (EMD
Biosciences) and inclusion bodies (IB) were harvested by
centrifugation of the lysate at 15,000 x g. IB pellets were
washed twice and stored at -80 °C until purification (typically 24
hours or less). IB pellets were solubilized in 8 M guanidine
hydrochloride (GuHCl) in 100 mM NaPO4 and 10 mM Tris pH
8.0, clarified by centrifugation at 15,000 x g for 15 min and
added to Super Flow Ni-NTA resin (Qiagen) pre-equilibrated
with denature buffer (6.0 M GuHCl, 100 mM NaPO4, 10 mM
Tris pH 8.0). Denatured SHrPrP and Ni-NTA resin was
incubated by rotating at room temperature for 45 min and then
added to an XK FPLC column (GE Healthcare). Refolding was
achieved on column using a linear refolding gradient of
denature buffer to refold buffer (100 mM NaPO4, 10 mM Tris
pH 8.0) over 340 ml at 0.75 ml/min. SHrPrP was eluted with a
linear gradient of refold buffer to elution buffer (100 mM
NaPO4, 10 mM Tris pH 8.0 500 mM imidazole pH 5.5) over
100 ml at 2.0 ml/min. Fractions were pooled and dialyzed
against two changes of 4.0 l dialysis buffer [20 mM NaPO4 pH
5.5 (CSU); 10 mM NaPO4 pH 5.8 (RML)]. SHrPrP was adjusted
to ~0.5 mg/ml, aliquoted, snap frozen in liquid nitrogen, and
then stored at -80 °C.
Animals and samples
All animals were handled in strict accordance with guidelines
for animal care and use provided by the United States
Department of Agriculture (USDA), National Institutes of Health
(NIH) and the Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC), and all animal
work was approved by Colorado State University Institutional
Animal Care and Use Committee (IACUC approval numbers
02-151A, 08-175A, 09-1463A, 10-1766A, 10-2189A, 11-2622A
and 12-3773A).
The CWD-naïve, hand-raised, human- and indoor-adapted
white-tailed deer fawns were sourced from the Warnell School
of Forestry, University of Georgia as part of longstanding
collaborations with David Osborn, Sallie Dahmes, Carl Miller
and Robert Warren. The deer were housed in indoor barrier-
maintained pens at the Colorado State University CWD
Research Facility at the Foothills Campus. As part of CWD
transmission, pathogenesis, and vaccination studies, they were
exposed to CWD prions contained in various inoculation
materials delivered by various routes (Table 1). Saliva samples
were collected via syringe aspiration or direct tube collection
predominantly from anesthetized deer and stored at -80 °C
until thawing and dilution for the assays described. The
majority of samples forming the basis of this report were
analyzed independently using the same QuIC protocols in the
CSU and NIAID/Rocky Mountain laboratories by the first two
authors of this report (Table S1). Deer were classified clinically
(Table 1) as: (a) pre-clinical—either no symptoms of CWD or
behavioral changes sufficiently subtle as to be detectable only
by observers experienced with each animal and its demeanor;
(b) clinical—varying levels of clinical CWD signs were present,
including: weight loss of >10% peak weight, behavioral
changes (e.g. postural changes, fixed staring, repetitive
motions, aggression or withdrawal), increased frequency of
food or water consumption, incoordination, salivation.
Diluted saliva RT-QuIC assay
The substrate for seeded RT-QuIC reactions was prepared
by adding SHrPrP to RT-QuIC reaction buffer composed of 50
mM NaPO4, 320 mM NaCl, 1.0 mM ethylenediaminetetraacetic
acid tetrasodium salt (EDTA), 10 µM Thioflavin T (ThT, Sigma)
to a final concentration of 0.1 mg/ml. The substrate was added
to optical bottom black 96-well plates (Nunc) with either 98 µl
for brain homogenate samples or 95 µl for 1:10 dilution
(Dilution buffer: 0.1% SDS in PBS pH 7.4) saliva samples. 2 µl
of CWD positive or negative control brain samples diluted from
10-4 to 10-8 were added to substrate on each plate. Five µl of
1:10 diluted saliva was added in quadruplicate to substrate
RT-QuIC Detection of CWD Prions in Saliva
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Table 1. Summary of white-tailed deer sample status and
RT-QuIC results.
Animal DilutedPTA Animal Route PrPRes
Disease
State
NumberSaliva Saliva Inoculum  IHC#  
108 0/8 0/8 CWD(+) Blood IP/IV + Terminal
112 1/8 8/8 CWD(+) Brain PO + Clinical
121 2/8 8/8 CWD(+) Brain IC + Terminal
132 0/8 8/8 CWD(+)Saliva PO + Terminal
133 5/8 8/8 CWD(+) Blood IV + Clinical
136 0/8 6/8 CWD(+) Brain PO + Terminal
137 0/8 4/8 CWD(+) Blood IV + Clinical
138 3/8 10/12 CWD(+) Brain PO + Clinical
143 0/8 1/8 CWD(+) Brain PO + Terminal
144 3/8 8/8 CWD(+)Saliva PO + Terminal
773 0/8 3/8 CWD(+) Brain PO + Pre-Clinical
775 1/8 0/8 CWD(+) Brain PO + Pre-Clinical
776 0/8 8/8 CWD(+) Brain PO + Pre-Clinical
777 1/8 2/12 CWD(+) Brain PO + Pre-Clinical
778 1/8 12/12 CWD(+) Brain PO + Pre-Clinical
780 0/8 1/8 Ovine Scrapie (+)Brain IV + Pre-Clinical
781 0/8 0/8 CWD(+) Brain PO + Pre-Clinical
785 1/8 12/12 CWD(+) Brain PO + Pre-Clinical
812 1/8 0/8 CWD(+) Brain Aerosol + Pre-Clinical
813 0/8 16/16 CWD(+) Brain Aerosol + Pre-Clinical
815 1/8 8/8 CWD(+) Brain Aerosol + Pre-Clinical
816 3/8 0/8 CWD(+) Brain Aerosol + Pre-Clinical
817 1/8 6/8 CWD(+) Brain Aerosol + Pre-Clinical
818 1/8 2/8 CWD(+) Brain Aerosol + Pre-Clinical
810 0/8 0/8 (-) Brain Aerosol - N.A.
814 0/8 0/8 (-) Brain Aerosol - N.A.
819 0/8 0/16 (-) Brain Aerosol - N.A.
103 0/8 0/8 (-) Multiple* Var.Routes - N.A.
123 0/8 0/8 (-) Multiple* Var.Routes - N.A.
502 0/8 0/12 (-) Urine & Feces PO - N.A.
504 1/8 1/8 (-) Urine & Feces PO - N.A.
Summary of animals, inocula and route of infection, sample collection relative to
clinical status, and RT-QuIC results. The number of replicates positive from up to 3
experiments is reported for both 1:10 diluted saliva and PTA treated saliva.
Definitions: Pre-clinical—either no symptoms of CWD or behavioral changes
sufficiently subtle as to be detectable only by observers experienced with each
animal and its demeanor; Clinical—varying levels of clinical CWD signs were
present, including: weight loss of >10% peak weight, behavioral changes (e.g.
postural changes, fixed staring, repetitive motions, aggression or withdrawal),
increased frequency of food or water consumption, incoordination, salivation.
Inocula abbreviations: intraperitoneal (IP), orally (PO), intravenously (IV),
Intracranially (IC). (*) Animals received multiple (-) inocula. Each received CWD (-)
blood IP, CWD (-) urine, feces and saliva PO and CWD (-) white-tailed deer brain
IC.
doi: 10.1371/journal.pone.0074377.t001
wells for each assayed saliva sample. Each saliva sample was
assayed in quadruplicate wells at least twice using
independently set up substrate reaction mixes. Prepared plates
were placed in a BMG Labtech Polarstar™ fluorometer and
subjected to 700 rpm double-orbital shaking for one minute
every other minute for 15 minutes. After each shaking cycle
ThT fluorescence was read at an excitation of 450 nm and
emission of 480 nm. Gain was set at 1700 for 1:10 dilution
saliva samples and read using orbital averaging with 20 flashes
per well with the 4 mm setting. The substrate was replaced
after 24 hours by removing 100 µl from each well. A residual
amount of liquid remained in each well and a high percentage
of the ThT fluorescence. Fluorescent readings were recorded
for all sample reactions for a total time of 48 hours at a
temperature of 42 °C.
PTA saliva RT-QuIC assay
In order to concentrate CWD prions and avoid the assay
inhibition factors in saliva, 100 µl of each sample was shaken
for 1 hour at 1500 rpm and 37 °C (Eppendorf Thermomixer R)
in the presence of 0.28% (w/v) phosphotungstic acid (PTA,
Sigma) at pH 7.4. After a 30-min spin at 16100 x g at 23 °C, the
pellet was resuspended in 10 µl of 0.1% (w/v) SDS/PBS and
used as seed for the RT-QuIC reaction.
RT-QuIC reaction substrate composition was as follows: 10
mM phosphate buffer (pH 7.4), 300 mM NaCl, 0.1 mg/ml
SHrPrP, 10 µM ThT, and 1 mM EDTA. Ninety-eight µl of
substrate was loaded into wells of a black 96-well plate with a
clear bottom (Nunc) and seeded with a 2 µl seed sample for a
final reaction volume of 100 µl. All reactions contained
equivalent final concentrations of SDS (0.002%). The plates
were sealed with a plate sealer film (Nalgene Nunc
International), and then incubated in BMG Labtech FLUOstar™
plate reader at 46 °C for 65 hours with cycles of 1 min shaking
(700 rpm double orbital) and 1 min rest throughout the
incubation. ThT fluorescence measurements (450 +/-10 nm
excitation and 480 +/-10 nm emission; bottom read, 20 flashes
per well, manual gain of 2300, and 20 ms integration time)
were taken every 45 min.
Mouse inoculation studies
Four milliliters of saliva was collected from two
experimentally exposed white-tailed deer (deer #133, 12mos
post-inoculation, and 144, 27mos post-inoculation) and one
sham exposed white-tailed deer (123). Saliva samples were
lyophilized using a LabConco lyophilizer, resuspended in 0.4
ml of PBS and dialyzed against PBS to return the samples to
isotonicity. Four milliliters of saliva from a negative control deer
(deer 123) was prepared concurrently in a similar fashion.
Three groups of Tg[CerPrP] 5037 mice [37] (n=9 mice/group)
were sedated using an intraperitoneal (IP) injection of 500 µl of
ketamine (10 mg/ml) and xylazine (1 mg/ml), and inoculated
intracranially (IC) with 30 µl of the concentrated saliva
preparation. Each group was inoculated with concentrated
saliva from a single source animal (#133, 144, or 123).
Following inoculation, mice were monitored daily over the
course of disease for evidence of prion infection
(incoordination, weight loss, etc.) and humanely euthanized
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when necessary. Following euthanasia, the left hemisphere of
the brain was removed and analyzed for the presence of PrPRes
by western blotting.
Western blotting
The left hemisphere of each cervid brain was divided into 8
rostral to caudal sections for analysis by western blotting. The
most rostral region of all 8 slices was prepared as a 10%
homogenate suitable for western blotting. Each sample was
processed with and without proteinase K (PK; 30 µg/ml)
addition for 30 min at 37 °C shaking at 850 rpm. After PK
treatment samples were electrophoresed in 12% SDS-PAGE
gel (Biorad), transferred to PVDF with the Trans-Blot Turbo
semi-dry transfer apparatus (Biorad). Membranes were
processed with the Snap-ID™ western blot instrument
(Millipore), blocked with Snap-ID blocking reagent (Millipore),
and probed with BAR-224-HRP conjugated antibody at a
concentration of 1:5000. HRP blots were developed with Pierce
ECL-plus™ reagent (Thermo Scientific) and imaged on an
Image-Quant LAS-4000™ imager (GE Scientific).
End-point dilution analysis
End-point dilution analysis was performed as follows. Two
microliters of 10-7, 10-8 and 10-9 CWD-positive and 10-7 normal
deer brain homogenate in dilution buffer were loaded into the
RT-QuIC reaction. For each dilution, 12 replicates wells were
seeded. Three aliquots (100 µl) of each CWD negative and
positive brain homogenate dilutions were PTA precipitated and
PTA pellets resuspended in 10 µl of 0.1% (wt/vol) SDS/PBS; 4
wells were seeded with 2 µl of each PTA pellet. RT-QuIC and
PTA precipitation were performed as described in PTA saliva
RT-QuIC paragraph, Materials and Methods section.
Results
RT-QuIC can detect CWD prion seeds in a 1:10 dilution
of saliva
Our first goal was to employ the RT-QuIC method for
detection of CWD prions in diluted saliva from CWD-inoculated
deer. We initially assayed saliva samples diluted from 10-1 to
10-3. No sample diluted past 10-1 yielded a positive result in the
RT-QuIC assay, inferring, consistent with previous bioassay
studies, a relatively low concentration of prions relative to
tissue sources. Nevertheless, we identified a number of saliva
samples which at 1:10 dilution in dilution buffer were routinely
positive with RT-QuIC. In each of two experiments multiple
replicates of these saliva samples were positive with
magnitudes and kinetics equivalent to 10-6 to 10-8 dilutions of
CWD positive brain homogenate (Figures 1 and 2). Saliva
samples were deemed positive if the average end-point ThT
fluorescence of four replicate wells was 3 standard deviations
greater than the average fluorescence of the negative control
saliva samples. The threshold for positivity with 1:10 diluted
saliva, and for PTA-precipitated saliva (see below), was
calculated based on the negative controls performed for each
method. However, diluted saliva samples from 5 of 10 animals
that were known to have clinical CWD symptoms and tonsil or
rectal lymphoid tissues positive for CWD PrPRes by
immunohistochemistry or western blot were not positive by RT-
QuIC (Figure 1 and Table 1). While this could represent the
heterogeneity inherent in single time point saliva collections,
we nevertheless sought to enhance the salivary RT-QuIC
sensitivity without introducing complex concentration methods.
PTA/RT-QuIC enhances detection of CWD prion seeds
in saliva
With the goal of enhancing the sensitivity of CWD prion
detection in saliva (~50% in known infected deer, Table 1)
without compromising specificity or introducing cumbersome
methodologies, we added pre-assay phosphotungstic acid
(PTA) precipitation of saliva samples to the RT-QuIC protocol.
PTA precipitation of CWD positive brain spiked into deer saliva
samples decreased the lag phase of RT-QuIC reactions
(Figure 3A) and increased sensitivity by approximately one
order of magnitude (Figure 3B). None of the wells seeded with
normal deer brain homogenate or their 3 independently PTA
precipitated counterparts gave ThT positivity, showing that the
unseeded SHrPrP was stably non-amyloidogenic within the
RT-QuIC conditions we used (NaCl 300-320 mM, 42-46 °C, 65
hrs) and that the PTA precipitation protocol per se did not lead
to false positive results (Figure 3 A and B). PTA precipitation
also reduced spontaneous conversion seen with some
undiluted negative control saliva samples, potentially by
eliminating or reducing reaction competitors or inhibitors found
in saliva, blood and urine. With the addition of PTA
precipitation, the same saliva samples from the above group of
clinically ill animals retained the same specificity and increased
sensitivity from 50 to 90% (5/10 to 9/10) (Figure 1 and Table 1).
Both RT-QuIC assay methods showed only a single apparent
false positive replicate out of 56 for 1:10 diluted samples and 1
of 68 for PTA precipitation. Each method detected the false
positive in the same saliva sample, which likely reflects a
predisposition of that sample to cause spontaneous conversion
due to contaminants such as rumen or fomites.
RT-QuIC-positive saliva samples contain infectious
prions
To establish that saliva samples positive for CWD prion
seeds by RT-QuIC assay contained authentic infectious CWD
prions, transgenic mice expressing normal cervid PrPC
(Tg[CerPrP] 5037 mice) [37] were inoculated intracranially with
the same saliva samples tested by RT-QuIC from two of the
above deer (#133 and 144 from Figure 1). Mice inoculated with
each positive saliva sample developed clinical symptoms of
TSE as early as ~300 days post-inoculation (dpi) and 50% of
the mice were euthanized due to signs attributed to prion
infection by 500 dpi, as confirmed by western blotting for PrPRes
(Figures 4 and S1). Mice inoculated in the same manner with
saliva from an uninfected animal did not develop clinical TSE
symptoms nor was PrPRes detectable by western blot (Figures 4
and S1).
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RT-QuIC-based detection of prion shedding in pre-
clinical deer
One of our research goals was to establish/develop a non-
invasive means to monitor the peripheralization and excretion
of prions throughout the CWD disease course. Using parallel
analysis of the same saliva samples tested by both 1:10
dilution and PTA-precipitation from pre-clinical CWD-inoculated
white-tailed deer in two laboratories, we detected CWD prion
shedding in 64.2% of 1:10 diluted samples and 71.4% of PTA
precipitated samples (Figure 5 and Table 1). PTA increased
the number of positive well replicates from 9.8% with 1:10
dilution to 53.0% and decreased the time for ThT fluorescence
to cross the threshold. However, three samples (deer# 775,
812 and 816) that were not positive by PTA RT-QuIC showed a
positive signal in the dilution tested samples (Figure 5 and
Table 1). These differences may reflect degradation of
protease sensitive material during the PTA protocol since no
protease inhibitors are used but more work will be necessary to
understand the mechanism.
Correlation of salivary shedding with magnitude of
prion dissemination in brain
In the course of analyzing both pre-clinical and terminal
saliva samples from white-tailed deer, we observed that saliva
from some animals produced more robust and consistent
positive results by both the PTA and 1:10 diluted RT-QuIC
protocols. Because terminal brain was available from most
animals, we compared prion dissemination and burden,
estimated by western blotting of 8 rostral to caudal brain slices
from deer after they had developed terminal disease to RT-
QuIC results from the preclinical stage of disease (Figure 6A, B
and S2). Widespread distribution and increased magnitude of
Figure 1.  RT-QuIC analysis of CWD-positive clinically ill white-tailed deer.  Both 1:10 diluted and PTA precipitated saliva show
positive results by RT-QuIC. Each line represents an individual experiment with the average of four replicates. Blue and light blue
lines represent 1:10 diluted saliva experiments and red and dark red lines represent PTA precipitated counterpart of the same saliva
samples. The left axis (blue) denotes ThT fluorescence for 1:10 diluted saliva samples and the right axis (red) denotes ThT
fluorescence for PTA saliva samples. Dashed lines represent threshold for a positive sample. Blue for 1:10 diluted saliva
experiments and red for PTA saliva experiments. Positive RT-QuIC results were observed for saliva from clinically ill white-tailed
deer in 5 of 9 1:10 diluted saliva samples and 8 of 9 PTA precipitated saliva samples. Each saliva sample was from an individual
deer.
doi: 10.1371/journal.pone.0074377.g001
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PrPRes at terminal disease state was often observed for animals
with the most RT-QuIC positive saliva replicates during the
preclinical stage of disease suggesting a potential correlation
between shedding and central nervous system prion load
(Figure 6B and S2). Since the western blot data are not
quantitative, a strong conclusion regarding direct correlation is
not possible, although it would not be surprising that a higher
prion load in the brain would lead to higher prion levels shed in
saliva.
Discussion
We demonstrate that RT-QuIC can reproducibly detect
prions in saliva, a complex biological fluid containing a wide
range of complex glycoproteins including proteases [38–40].
Two of two RT-QuIC-positive saliva samples contained
infectious prions by Tg[CerPrP] mouse bioassay and PrPRes
distribution in the brain seemed to correlate with RT-QuIC
positivity. PTA enrichment of CWD prions in saliva increased
the percentage of positive replicates from 17.5% in clinical
animals tested by dilution of untreated saliva to 72.6% and
from 9.8% in diluted saliva from pre-clinical animals to 53.0%.
Previous studies by Colby et al. [41] demonstrated that PTA
inhibited amyloid amplification in the amyloid seeding assay.
Our results suggest that under the present assay conditions
PTA precipitation is not inhibitory but rather increases the
sensitivity (Figure 3A and B), perhaps by both concentrating
the prions from more saliva equivalents and decreasing saliva-
associated inhibitory activities (Figure 3A).
Figure 2.  SHrPrP substrate can detect CWD-positive brain over a range of dilutions from 10-4 to 10-7.  CWD positive and
negative brain was serially diluted and analyzed by RT-QuIC assay. Each line for positive CWD samples represents the average of
4 individual wells from 4 independent experiments.
doi: 10.1371/journal.pone.0074377.g002
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Figure 3.  PTA precipitation increases sensitivity of the RT-QuIC assay.  A. Each data point shows the ThT fluorescence
average of 4 replicate wells loaded with either 2 µl of brain homogenate dilution or PTA pellets from the same brain homogenate
equivalents. Lines with triangles represent PTA precipitated samples while smooth lines are non-precipitated counterparts or
controls (in the latter case, invisible under the green triangles). The data for spiked PTA precipitated deer saliva (purple triangles)
comes from a separate experiment performed under the same experimental conditions. B. End-point dilution analysis of a CWD (+)
brain homogenate including 10-7 to 10-9 dilutions with or without PTA precipitation. PTA precipitated samples were done in triplicate
(purple) and represent the ThT fluorescence average of 4 replicate wells each. Non-precipitated samples (red) represent the ThT
fluorescence average of all 12 replicate wells. Normal deer brain homogenates (green) are shown for PTA precipitated (3
overlapping curves of data points representing the average of 4 replicate wells) and non-precipitated (average of 12 replicate wells)
samples.
doi: 10.1371/journal.pone.0074377.g003
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Horizontal transmission of CWD is exceptionally efficient,
which may be why it is the only known prion disease found in a
free-ranging animal species [42,43]. Enhanced horizontal
transmission may reflect abundant excretion and/or unique yet
elusive biochemical features of prions shed by CWD infected
deer. Multiple studies have demonstrated that relatively
protease sensitive and/or oligomeric conformers of PrPC are
both infectious and perhaps the more pathogenic species in
prion disease [44–48]. Elucidating biochemical differences of
prions from saliva or excretory products (e.g. nasal secretions)
with the help of the RT-QuIC may reveal possible structural or
stability differences between prions in the central nervous
system and those shed into the environment.
Several studies indicate that the concentration of prions in
excreta is very low, thus requiring multiple rounds of
amplification in PMCA as well as sample dilution to escape
inhibitors [10,29,49,50]. Because RT-QuIC methodology offers
the advantages of single cycle amplification, it offers potential
for high through-put and reduced contamination risk-
advantages for both detection and surveillance in the natural
setting and in controlled longitudinal studies of prion
pathogenesis and excretion. As estimated by the kinetics and
magnitude of RT-QuIC responses, it appears that the
concentration range of prions in saliva is approximately
equivalent to 10-6 to 10-8 dilutions of CWD-positive brain. These
results reinforce previous studies indicating that RT-QuIC can
estimate the relative concentrations of infectious prions in a
given sample [34].
Bioassay experiments also indicate that the levels of
infectious prions in deer and sheep saliva are similar to near
end-point dilutions of prion-infected brain [13,26]. Although
complicated by the presence of inhibitors, blood-borne prions
have been demonstrated through substantial dilution prior to
assay or use antibody capture from plasma to both concentrate
seeding activity and escape inhibitors [12,29,30,50].
Conversely, cerebrospinal fluid has been shown to have
relatively high levels of prion seeding activity [11,51]. Overall,
therefore, the results we report here for saliva using RT-QuIC
are consistent with studies thus far employing in vitro
amplification methods.
However, much as with PMCA, comparing the relative
amplification of saliva samples to brain samples or any other
sample from tissue or body fluid has a number of caveats. For
example, each sample source potentially contains distinct
amplification inhibitors, enhancers, as well as other factors that
likely influence reaction rate, magnitude, or lag phase.
Nevertheless, the comparisons between in vitro seeding
assays and in vivo infectivity assays increasingly support
careful extrapolations.
In summary, RT-QuIC offers sensitivity with relatively rapid
single cycle amplification, versatility in application to tissues,
biologic fluids, and environmental samples, and potential to
define co-factors and inhibitors of prion conversion.
Figure 4.  Kaplan-Meier survival curve for mice inoculated with CWD+ saliva.  The same saliva samples from deer assayed in
Fig. 1 (#133 and 144) were inoculated into cervidized mice (Tg[CerPrP] 5037) as well as saliva from a sham inoculated deer. 50%
of mice were euthanized due to clinical disease after ~500 days.
doi: 10.1371/journal.pone.0074377.g004
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Figure 5.  RT-QuIC comparison of diluted saliva vs. PTA precipitated saliva harvested from pre-clinical* white-tailed
deer.  PTA precipitation of saliva samples increased sensitivity and consistency of RT-QuIC prion detection of pre-clinical white-
tailed deer. All colors and axis are the same as in Figure 1. (*) refers to either no signs of CWD or subtle behavioral symptoms
detectable only by observers very familiar with individual deer and the very early signs of CWD.
doi: 10.1371/journal.pone.0074377.g005
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Figure 6.  Correlation of RT-QuIC analysis of terminal saliva samples with western blot PrPRes signal in brains.  A. Cartoon
representation of sections analyzed for PrPRes by western blotting. Seven rostral to caudal sections were analyzed plus the obex/
brainstem region. B. (left) RT-QuIC analysis of saliva samples from white-tailed deer. Colors and axis are the same as in Figure 1
(right). Western blot analysis of 8 brain sections including CWD (+) and (-) control samples. PK was added to all samples except
one CWD (-) brain sample. Antibody BAR-224-HRP used for detection.
doi: 10.1371/journal.pone.0074377.g006
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Supporting Information
Figure S1.  Western blot analysis of CWD(+) saliva
inoculated Tg[CerPrP] 5037 mice. Lanes 1 and 18 show
PrPC form 10% mouse brain homogenates without PK
digestion. Big arrowhead marks location of undigested
PrPC. Lanes 2-17 are PK digested brain homogenates from IC
inoculated mice. Lanes 2-5 are brain homogenates from mice
IC inoculated with obex from deer #133. Lanes 6-9 are brain
homogenates from mice IC inoculated with saliva from deer
#133. Lanes 10-13 are brain homogenates from mice IC
inoculated with saliva from deer #144. Lanes 14-17 are brain
homogenates from mice IC inoculated with saliva from deer
#123 a mock infected CWD(-) deer.
(TIF)
Figure S2.  Brain section western blot analysis of deer
tested preclinically for prions in saliva. A. PrPRes western
blot analysis of deer with 100% of PTA RT-QuIC positive
replicates. B. Western blot PrPRes analysis of deer with less
than 100% of PTA RT-QuIC positive replicates. PK was added
to all samples except one CWD(-) brain sample. Antibody
BAR-224 was used for detection. Layout of western blots is the
same as in figure 6.
(TIF)
Table S1.  Summary of RT-QuIC results. Comparison of
RT-QuIC results from dilution or PTA experiments
performed in laboratories at CSU and RML.
(DOCX)
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Animal 
Number 
CSU 
Diluted 
Saliva 
CSU 
PTA 
Saliva 
RML 
Diluted 
Saliva 
RML 
PTA 
Saliva 
108 0/8 0/8 0/4 0/8 
112 1/8 4/8 0/4 8/8 
121 2/8 0/8 N.T. 8/8 
132 0/8 1/8 N.T. 8/8 
133 5/8 8/8 N.T. 8/8 
136 0/8 2/8 1/4 6/8 
137 0/8 N.T. N.T. 4/8 
138 3/8 5/8 4/4 10/12 
143 0/8 N.T. 0/4 1/8 
144 3/8 8/8 N.T. 8/8 
773 0/8 0/8 0/4 3/8 
775 1/8 1/8 0/4 0/8 
776 0/8 7/8 0/4 8/8 
777 1/8 0/8 0/4 2/12 
778 1/8 5/8 0/4 12/12 
780 0/8 3/8 0/4 1/8 
781 0/8 0/8 0/4 0/8 
785 1/8 3/8 0/4 12/12 
812 1/8 1/8 0/4 0/8 
813 0/8 1/8 0/4 16/16 
815 1/8 3/8 0/4 8/8 
816 3/8 N.T. N.T. 0/8 
817 1/8 N.T. N.T. 6/8 
818 1/8 N.T. N.T. 2/8 
810 0/8 0/8 N.T. 0/8 
814 0/8 0/8 N.T. 0/8 
819 0/8 0/8 N.T. 0/16 
103 0/8 N.T. N.T. 0/8 
123 0/8 N.T. N.T. 0/8 
502 0/8 0/8 0/4 0/12 
504 1/8 1/8 0/4 1/8 
 
Table S1. Summary of RT-QuIC results. Comparison between dilution and PTA experiments 
performed in laboratories at CSU and RML, expressed in number of positive wells/total wells tested. 
N.T. is not tested. 
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Figure S1. Western blot analysis of CWD(+) saliva inoculated Tg[CerPrP] 5037 mice. Lanes 1 
and 18 show PrPC form 10% mouse brain homogenates without PK digestion. Big arrowhead 
marks location of undigested PrPC. Lanes 2-17 are PK digested brain homogenates from IC inoculated 
mice. Lanes 2-5 are brain homogenates from mice IC inoculated with obex from deer #133. Lanes 6-9 
are brain homogenates from mice IC inoculated with saliva from deer #133. Lanes 10-13 are brain 
homogenates from mice IC inoculated with saliva from deer #144. Lanes 14-17 are brain homogenates 
from mice IC inoculated with saliva from deer #123 a mock infected CWD(-) deer. 
 
 
 
64
 
 
Figure S2. Brain section western blot analysis of deer tested preclinically for prions in saliva. A. 
PrPRes western blot analysis of deer with 100% of PTA RT-QuIC positive replicates. B. Western blot 
PrPRes analysis of deer with less than 100% of PTA RT-QuIC positive replicates. PK was added to all 
samples except one CWD(-) brain sample. Antibody BAR-224 was used for detection. Layout of western 
blots is the same as in figure 6. 
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